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Abstract
Background: In July 2014, New York State became the 23rd state to legalize marijuana
(“cannabis”) for medical consumption under the New York State Medical Marijuana Program
(“Program”). Three years later, during his Executive budget address, the NYS Governor,
Honorable Cuomo, directed the Department of Health in consultation with other NYS agencies,
to evaluate the experience, consequences and effects of legalized marijuana in neighboring states
and territories, and to review the health, criminal justice and economic impacts of regulating
marijuana use. That report concluded that the positive effects of a regulated marijuana market
outweighed the potential negative impacts.
Objective: This dissertation has three aims. First, to study emerging trends in the
experiences of a convenience sample of 12 stakeholders accessing and utilizing the New York
States’ Program.
Second, to study the cost-effectiveness of medical cannabis in combination with the
opioid pharmacotherapy compared to the standard of care employing opioids alone from a
healthcare perspective with a time horizon of one year, in 2017 US$, with quality adjusted life
years gained as the primary outcome.
Third, to study the lived experiences of a cohort of 20 subjects with cancer-related
neuropathic pain who are generally being managed on opioid pharmacotherapy for cancerrelated pain in whom medical cannabis has been added to improve analgesia and diminish opioid
requirements.
Methods: Approval was given by the City University School of Public Health, Human
Research Protection Program for research designs to address the three study objectives.
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The first study was designed as a qualitative cross-sectional study of stakeholders of
Vireo Health dispensaries in downstate New York that comprised entrepreneurs, physician
providers, pharmacists, and client stakeholders. In-depth, semi-structured phone interviews were
conducted following a topical guide instrument with major domains of stakeholders’ personal
views, community norms, attitudes, and behaviors, prescribing practices, knowledge of drug
cost, insurance coverage, and financial subsidies, pharmacy and dispensing processes. Primary
data was analyzed on Dedoose® with the compilation of a codebook and coding of transcripts to
yield emergent themes that were in turn triangulated.
The second study was designed as a cost-effectiveness analysis using a decision tree in
TreeAge Pro to simulate the cost and clinical outcomes of adding medical cannabis treatment for
chronic sickle cell disease pain compared to the standard of care using opioid analgesic
medication alone. Probabilities, costs, and quality of life utility weights associated with opioid
use and chronic pain among patients treated with medical cannabis versus standard of care were
derived from published literature. Primary outcomes included medication costs and healthrelated quality of life (measured in adjusted life years, QALYs). The analysis was carried out
from a healthcare sector perspective with a time horizon of one year. Medication costs associated
with chronic pain treatment involving cannabis and opioids expressed in 2017 US$. Incremental
cost-effectiveness ratios were calculated by comparing cannabis-assisted treatment with opioidonly standard of care. One-way sensitivity analyses and threshold analyses were performed to
assess parameter uncertainty.
The third study was designed as a qualitative cohort study of the lived experiences of a
convenience sample of subjects who met the eligibility criteria of age 21 or older, English
speaking, under the care of a pain management health provider, not pregnant or breast-feeding,
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and the diagnosis of cancer-related neuropathic pain. Study subjects were all served by a single
upstate Vireo Health dispensary to add medical cannabis to a standard of care regimen to
improve analgesia and reduce the need for opioids. The subjects underwent semi-structured indepth phone interviews using a topic guide covering domains related to experiences of cancer
and treatment, experiences and perceptions of pain management strategies, and impacts on
quality of life. Thematic analysis was conducted with coding by hand using Microsoft Word.
Coded excerpts were copied into a themes matrix in Excel where emerging trends were critically
analyzed according to the study aims.
Results: Chapter 2 studied 12 stakeholders of the New York State Medical Marijuana
Program and revealed emergent themes centered on facilitators and barriers for the acceptance,
accessibility and use of medical marijuana in New York. Facilitators included effectiveness and
safety, while barriers included stigma, process, and cost. The effectiveness of medical marijuana
as a medication for various conditions and was highlighted as a major facilitator for its
legalization, acceptance, and use). Additionally, participants noted the demonstrated safety of
marijuana as a medication, which has shown to be much safer than other legal drugs, and its use
in helping patients come off opioids. Stigma surrounding marijuana was identified as a barrier
with participants highlighting misperceptions or personal stigmas as a prohibitive to legalization,
acceptance, and use. There was frank criticism of NYS’ program by stakeholders evident in other
themes emerging around the processes involved in accessing and using the NYS Program.
Entrepreneurs were critical of the excessively bureaucratic process of the application and
registration process for opening dispensaries; and physicians were wary of the Program’s
educational bureaucratic program to become certified providers; and clients cited difficulty in
finding providers, assembling documentation, registering on the Program website, waiting for the
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certification card, arranging a pharmacist consultation at the dispensary, and among those
perceived stigmas of cannabis. Additionally, the cost of medical cannabis was voiced as
excessive by patients.
Chapter 3 study of the cost-effectiveness of adding medical cannabis treatment for
chronic sickle cell disease pain compared to the standard of care using opioid analgesic
medication alone found that cannabis-assisted treatment is estimated to reduce addiction by
11.5% among SCD patients previously addicted to opioids and improve chronic pain control
from 56% to 76%. On average, cannabis-assisted treatment increased monthly pain management
medication costs by $1781.21 per person compared to opioid analgesic treatment alone
($6037.61 vs. $4,256.40) and produced 0.06 more QALYs per person (0.58 vs. 0.52 QALYs).
The resulting incremental cost-effectiveness ratio was $27,219.78/QALY gained. Based on a
commonly used $100,000/QALY willingness-to-pay threshold, cannabis-assisted treatment was
very cost-effective compared to the opioid-only strategy. Sensitivity analyses suggested that
these results were robust against a wide range of parameter values.
Chapter 4 studied the use of medical cannabis in the management of cancer-related pain
from a single dispensary experience in upstate New York among 8 men and 12 woman with a
mean age 59.5 years with cancer-related neuropathic pain associated with lymphoproliferative
tumors, malignant cancer of the breast, lung, ovary, prostate, gallbladder, and skin. The majority
of subjects (80%) were taking opioid pharmacotherapy to treat severe neuropathic pain scored by
PEG and VAS (in 7 subjects) respectively 5.7/10 and 4.25/5 consistent with severe neuropathic
pain before adding oral (7 subjects), sublingual (2 subjects), or inhaled cannabis products (4
subjects), or in combination (7 subjects). The employment status was known in 18 subjects, 14 of
whom were not working due to disease disability (8 subjects) or retirement (6 subjects) while 4
4

others were working full-time (3 subjects) or part-time (1 subject). Emergent themes related to
the experiences of cancer and its treatment, perceptions and experiences of pain management
strategies, perceived benefits of medical cannabis, enablers of improved pain management, and
barriers to pain management. There was variability between and within individual’s experiences
of cancer pain and management strategies. Subjects often reported that opioid-based medications
fell short of providing sufficient pain control, were associated with severe or debilitating side
effects, or a mixture of the two. Cannabis-based medication provided a socially accepted, safe
and well-tolerated alternative to opioids in this cohort. The foremost challenge of the cohort was
in formulating their own strategy of pain management, combining available multimodality
aspects. Reported enablers for this included the availability of knowledge around cannabis-based
medication and their uses, as well as, moral, logistical, and financial support structures. Major
barriers to cannabis-based medication highlighted challenges resulting from its yet full
integration into the nation and state’s health systems that instilled inconsistencies in guidance,
access, and financial costs.
Discussion: New York State’s Program vertically integrates legislative and public health
policy of the positive effects of a regulated marijuana market in NYS that favorably influences
the optimal functioning of dispensaries, and outweighs its potential negative impacts to society,
communities, or individuals. However, there are significant barriers to stakeholders including
entrepreneurs, prescribing physicians and patients, even when they conform to state-mandated
program policies. This applies to dispensary ownership, provider and patient certification, and
accessing cannabis. There is stigmatization related to the acceptability of medical cannabis even
in the diseases for which it may be approved and deemed cost-effective, compared to the
standard of care therapies.
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Conclusion: The present dissertation compiles qualitative and quantitative public health
research based upon New York State’s Medical Marijuana Program. Viewed through the lens of
public health and a socioecological framework model, medical cannabis policy in New York
State should be framed, emphasizing it as an alternative to opioid pharmacotherapy in serious
disorders such as cancer- and sickle cell disease-related neuropathic pain, in which there is
favorable cost-effectiveness. Local communities and dispensaries can help frame acceptance
according to the principles of social reconstruction that highlight the interdependence of social,
environmental and individual biological determinants. At the societal level, there must be
support for cannabis in the struggle against the widening opioid crisis.
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Chapter 1: Introduction
Cannabis-Based Medication
“Marijuana” is the common (and legal) term for the dried flowers and leaves of the plant
Cannabis (C.) sativa (cannabis), and for the plant itself. The flowers contain concentrated
amounts of chemicals known as cannabinoids (produced only by this plant), terpenoids, and
flavonoids, the amount and mix of which vary with plant genetics, growing practices, and timing
of its harvest. It is one of the earliest plants cultivated by man for medicinal purposes (4).
Ancient Chinese cite cannabis in their pharmacopoeia as pen-tsar chin in the first century as an
anesthetic for surgery. Hindu Sanskrit texts cite it as a sacred plant called gañjā, derived from
flowers of the dry leaves of the sativa plant. The ensuing centuries saw the spread of cannabis to
the Middle East, Africa and Arabia, where physician texts cited it as a pain reliever and cleanser
of the brain. Later, 19th century physicians in Ireland and France (5, 6) delineated its analgesic
and psychoactive properties prior to recognizing its exact chemical structure and mechanism of
action. At the turn of the century, pharmaceutical companies in Germany, England and the
United States (US) (7) marketed products containing extracts of marijuana as “herbal cannabis”
and hashish, which were made by extracting cannabinoid-rich factors as a resin, while the term
“cannabis” remained a catchall term to the present, that includes both products.
The pharmacologic effects of cannabis-based medications (CBM) are attributed to the
actions of (-)-Trans-delta-9-tetrahydrocannabinol (THC) (8-14). Cannabidiol or CBD, equipotent
on cannabis type1 (CB1) receptors in the brain, and at opioid receptors in peripheral sensory
neurons, synergistically target the affective qualities of pain to enhance analgesia (15-17). Two
US Food and Drug Administration (FDA)-approved cannabinoid drugs available for prescription
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in the US: dronabinol (Marinol) Ⓡ, a synthetic THC compound, and nabilone (Cesamet Ⓡ), a
semisynthetic analog of Δ9-THC with an approximately 10 times greater potency than
dronabinol. While such drugs have shown some efficacy as an adjuvant analgesic, the sedating
and psychotropic properties of both agents limits their utility.
Nabiximols (Sativex Ⓡ), an oral spray that is an approximately racemic mixture of THC and
CBD, is approved for opioid-resistant, treatment-refractory cancer pain. It is a useful add-on
analgesic for patients with opioid-refractory cancer pain at low and medium doses.
The past two decades have witnessed extraordinary advances in the analgesic benefits of
cannabis-based medications employing randomized clinical trials (RCT) and meta-analyses
thereof. In 1999, the Institute of Medicine (IOM) assessed the medical value of medical cannabis
noting that opioid analgesic medications were limited by dose-related side effects and the
development of tolerance or dependence (18). The authors reviewed data from three double
blind, placebo-controlled RCT of cancer pain resistant to opioids (19). The studies cited
analgesia and pain relief by 10 mg of THC or its analogues in pill form equal to 60 mg of
codeine (20-22). In 2014, Koppel and colleagues (23) conducted a systematic review of RCTs of
cannabis-based medications through 2013 in the treatment of central pain, categorizing them
Class I to IV, from most to least robust according to the American Academy of Neurology (24).
The authors identified three prospective cohort (Class I) studies (25-27) of the efficacy of CBD
and THC alone or together in varying ratios, citing its efficacy.
In 2017, Aviram and Samuelly-Leichtag (28) conducted a systematic review and metaanalysis of published RCT up to 2015 in the treatment of neuropathic pain using any type of
CBM. Their analysis showed a reduction in pain of 20% to 50% compared to placebo. That same
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year, investigators at the National Academy of Science issued a report on the health effects of
cannabis and cannabinoids (29). The report included a review of two RCT of the treatment of
chronic pain due mainly to neuropathy, cancer, or multiple sclerosis, with cannabinoids and
synthetic THC (30, 31), noting a 40% increased odds for improvement compared to controls,
with effects that did not differ across pain conditions.
There is an urgency to integrate CBM into the multidisciplinary approach to chronic pain.
Hill and colleagues (32) reviewed the use of CBM noting that disorders associated with pain
ranked fifth among conditions cited by the Global Burden of Disease Study in 2010 (GBD 2010)
as a cause of years lived with disability (YLD) (33), accounting for a significant loss of QoL.
Two studies (34, 35) showed two to three-fold higher levels of use of healthcare services in
people with chronic pain than those without; and affected individuals cite modest clinically
relevant benefit from any one pharmacologic intervention in combating chronic pain (36),
suggesting the need for a multidisciplinary approach (37).
Several studies have addressed the use of CBM to reduce physician and patient reliance
on opioid pharmacotherapy in an effort to stem the growing opioid crisis. A 2014 National
Institute on Drug Abuse (NIDA)-funded study by Bachhuber and colleagues (38) developed
regression models of state and year fixed effects to examine percentage mean difference in ageadjusted opioid mortality rates per 100.000 population across states that failed to enact medical
cannabis laws, or did so prior to, or between 1999 and 2010. The authors reported lower rates of
overdose mortality that strengthened over time, from 19% in year 1, to 33% by year 6. These
results suggest that enactment of laws to allow for use of cannabis-based medications should be
part of a comprehensive package of policies to stem the opioid crisis. A second NIDA-funded
study by the RAND Corporation in (39) compared changes in opioid-related mortality and
17

treatment admissions in states adopting medical marijuana laws to those not adopting these laws.
The study combined a traditional difference-in-differences framework with descriptive national
vital statistics. It first replicated the results of Bachhuber and colleagues (38), and then extended
the analysis sample to include three more years of data (adding 2010 to 2013). In doing so, the
authors were surprised to find that late law adopters contributed to a further decline in opioid
overdose death rates from 2010 to 2013, due to the sale of CBM to qualified patients only.
The anticipated cost-savings and improvement in patients’ QoL are also compelling
reasons to make CBM available in all states. Using data on all prescriptions filled by Medicare
Part D enrollees from 2010 to 2013 Bradford and (40) examined prescription drugs for which
marijuana could serve as a clinical alternative, including chronic pain in seventeen states and the
District of Columbia. The authors used a simple difference-in-differences regression framework
to estimate each category of prescription drug use and found an overall national reduction in
Medicare program and enrollee spending of $165.2 million, with the highest component due to
analgesic drug use. If the remaining states were to have adopted a medical marijuana law by
2013, total spending by Medicare Part D would have been an estimated $468.1 million less, or
0.5% of all Medicare Part D spending in 2013.

Neuropathic Pain
Neuropathic pain is regarded as pain arising as a direct consequence of a lesion or disease
affecting the somatosensory system. Central neuropathic pain originates from damage to the
brain or spinal cord, while peripheral neuropathic pain stems from damage to the peripheral
nerve, plexus, dorsal root ganglion, or roots. Is further characterized by pain in the absence of a
18

noxious stimulus and may be spontaneous or evoked by sensory stimuli such as the light touch of
the skin resulting in allodynia. An array of potential pain mechanisms may be causative in a
given individual reflecting a combination of central and peripheral nervous system pathways.
Deconstructing neuropathic pain phenotypes shows an interplay of genetics, plasticity, neuronal
cognitive, autonomic and neuroimmunologic interactions and modulation.
A best estimate of the prevalence of pain with neuropathic characteristics in the general
population is 6.9% to 10%, with more precise estimates for specific associated conditions.
Neuropathic pain ranked fifth among conditions cited by the Global Burden of Disease Study in
2010 (GBD 2010) for YLD (41), further accounting for loss of QoL, employment, and increased
health costs. The most successful approaches to the treatment of neuropathic pain rely upon the
multidisciplinary rather than any one intervention (18, 23). Available pharmacologic
interventions topical lidocaine patch or low-concentration topical capsaicin, pain modulation
with antidepressants like duloxetine and amitriptyline (Elavil Ⓡ), or antiepileptics like
gabapentin (Neurontin Ⓡ) or pregabalin (Lyrica Ⓡ), but the proportion of patients who achieve
at least 50% relief is generally 10% to 25% more than with placebo (42).
Endocannabinoids serve as synaptic circuit breakers, regulating multiple physiological
and pathological conditions including central and peripheral neuropathic pain. They use the
brain's own cannabis-like substances, sharing the same molecular target as THC, the main
psychoactive component in cannabis. The benefit of cannabinoids in the management of
neuropathic pain is their favorable modulation of cognitive and autonomic processing and brain
signaling seen in chronic pain states, and their capacity to suppress behavioral responses to
noxious stimulation and nociceptive processing. The frontal-limbic distribution of CB1 receptors
in the brain suggests that cannabinoids preferentially target the affective qualities of pain. In
19

addition, cannabinoids may attenuate low-grade inflammation, another postulate for the
pathogenesis of neuropathic pain). Perhaps the most compelling reason to define the role of
CBM for control of pain and legalization of their use in all states is to reduce physician and
patient’s reliance on opioid pharmacotherapy for the treatment of chronic neuropathic pain.
The causes of neuropathic pain can be triggered by endocrinologic (diabetes and thyroid
disease), connective tissue diseases (lupus, Sjogren syndrome), infectious (malaria) and postinfectious autoimmune disorders (human immunodeficiency virus type 1 [HIV-1), Lyme disease,
syphilis, tuberculosis, herpes), genetic disorders (Fabry disease), and cancer (carcinoma,
lymphoma) each with a specific treatment. However, the resulting pain associated with each is
treated similarly according to 2016 standard clinical practice guidelines (43) beginning with
topical lidocaine, compound creams, and capsaicin patches, and progressing to oral tricyclic
antidepressants (TCA), pregabalin, and gabapentin, and later incorporating opioids. Regardless
of the order of first-, second- and third-line agents, The Second European Federation of
Neurological Societies Task Force found similar efficacy for most agents alone and in
combination using a Cochrane Database and Medline search class I and II RCTs (44). More
recently, medical cannabis emerged as an alternative in patients with non-cancer and cancerassociated neuropathic pain who do not respond well to opioids or have side effects from the use
of traditional analgesics (45).
An analysis of 29 subjects with severe chronic pain approved for medical cannabis in
New York State (46) associated with spinal cord injury (20 subjects), cancer (3 subjects),
neuropathy (3 subjects), inflammatory bowel disease (2 subjects), and Parkinson disease (1
subject) responded favorably in primary outcome measures of pain quality, with significant
reduction in opioid consumption and cost-savings. However, this study was limited by its
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retrospective nature, bias of small sample size and inclusion of a small number of unrelated
causes primarily spinal cord injury that limited its generalization to cancer or neuropathic pain.
Since the inception of the NYS Medical Marijuana Program (47) there has been only one
publication from the Department of Health, Wadsworth Center in Albany reporting on its status
(48) and that described product analysis. There has not been a review of its performance or
receptivity of dispensary stakeholder to date. Nor has there been a detailed analysis of its
performance in the management of neuropathic pain in particular cancer-related chronic pain.
Both of these represent gaps in the medical literature, which will be addressed in the present
dissertation.

Opioid-Based Medication
Opioid analgesic drugs often referred to as “opioids” or “narcotics” have the propensity
for both abuse and medicinal use (49). With pharmacologic properties similar to those of
morphine, they are highly lipophilic and pass readily across nasal membranes as well as the
blood-brain barrier where they act at opiate mu receptor agonists leading to euphoria and
analgesia (50). This has led to their widespread use in treating pain in the last two decades.
Opioids have become the most widely prescribed class of drugs in the US, with an estimated 245
million new prescriptions being filled in 2014 (51). However, rates of abuse have risen
dramatically. According to the most recent National Survey on Drug Use and Health (52) 11.8
million people (over 4% of the population) in 2016, aged 12 years or older in the US misused
prescription opioid drugs. In 2015, overdoses from both licit and illicit opioids resulted in over
33,000 deaths (45) and 750,000 emergency room (ER) visits were attributed to opioid abuse, making
it a significant public health burden. Further, patients who divert or abuse their opioid analgesic
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medications complicate long-term opiate prescribing. Overuse or abuse of opioids have fueled
the acronym opioid epidemic (53, 54). This ongoing epidemic lies at the nexus of two public
health challenges; improving patients’ health related QoL (HRQoL) through effective pain
management and reducing the growing burden and harm caused by abuse of these drugs.
Four historical developments have influenced the acceptance and availability of opioid
analgesic drugs in the US. First, the easing of restrictions governing the prescription of opioid
analgesic drugs by physicians for chronic pain treatment by state medical boards, in a process
that started in 1998 (49). Second, efforts beginning in the 1990s by the American Pain Society,
and two decades later by medical professionals (55) and the IOM (56) to recognize and reframe
pain management. Third, the availability of both opioid analgesics to treat pain and opioid
antagonists to treat opioid dependence (57). Fourth, the establishment of guidelines by the
Centers for Disease Control and Prevention (CDC) in 2016, for the safe dispensation of opioid
analgesic drugs by community primary care providers (58) and not just by pain management
experts. A year later, evidence-based standards of the Joint Commission of the Accreditation of
Healthcare Organization were published to improve the care of patients taking opioid analgesic
drugs for chronic pain (59), updating those of a decade earlier (60).
As a syndrome, pain is complex to understand, diagnose and manage and it is often
further complicated by comorbidities (61) such as diabetes and cancer which can make its
treatment more challenging. The added complexity presented by the potential for addiction and
side effects of opioids further complicate pain management.
Although preclinical evidence suggests cannabinoids increase the analgesic effect of
opioids, thus requiring a lower dose to achieve relief (62) a systematic review and meta-analysis
(63) showed inconsistent results in the opioid sparing effect of CBM, especially in cancer, biased
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in part by patients who may favor lower doses of CBM to avoid drug side-effects (64) and
physicians who discourage opioid dose reduction to maintain effective analgesia (65). This gap
in the literature of patient receptivity of CBM to improve analgesia independently and as
adjuvant therapy with opioids will be explored in this dissertation where the observational
analysis takes place outside of the RCT at the dispensary level.

Aims
Three study aims below have the overarching goals of understanding New York State’s
Medical Marijuana Program including its cost-effectiveness, potential for reducing opioid needs
with CBMs, and understanding the lived experiences of stakeholders in New York State may
give insights into affecting the opioid epidemic.
Aim 1: To study emerging trends in the experiences of a convenience sample of 12 key
stakeholders accessing and utilizing the medical marijuana program in NYS through Vireo
Health, Inc. The study participants will be identified by Vireo Health, chosen for their
willingness to participate in a research protocol without expectation of compensation for an indepth semi-structured interview including dispensary entrepreneurs, prescribing physicians,
pharmacists, and patients filling medical cannabis prescriptions in one or more dispensaries
managed by Vireo Health. Salient topics will include facilitators and barriers in the NYS
Medical Marijuana Program’s implementation process, and the registration paths for a referring
provider and the registration of qualifying patients.
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Aim 2: To study the cost-effectiveness of adding medical cannabis to opioid analgesic
medication in the management of chronic pain in patients with sickle cell disease using a
decision tree model analyzed in TreeAge Pro to simulate the cost and clinical outcomes.
Probabilities, costs, and quality of life utility weights associated with opioid use and chronic pain
among patients treated with medical cannabis versus the standard-of-care are derived from
published literature. Primary outcomes include medication costs and health-related quality of life
(measured in adjusted life years, QALYs). The analysis is carried out from a healthcare sector
perspective with a time horizon of one year. Medication costs associated with chronic pain
treatment involving cannabis and opioids are expressed in 2017 US$. Incremental costeffectiveness ratios are calculated by comparing cannabis-assisted treatment with opioid-only
standard-of-care. One-way sensitivity analyses and threshold analyses are performed to assess
parameter uncertainty .
Aim 3: To study the lived experiences of a convenience sample of 20 subjects with
cancer-related neuropathic pain who are generally being managed with opioids and who will be
adding medical cannabis to their regimen to improve analgesia and diminished opioid
requirements. Study subjects, all served by a single dispensary of Vireo Health located in
Binghamton, New York will undergo in semi-structures depth phone interviews to probe their
lived experienced from which emergent will be triangulated with their self-reported experiences
with CBM as an adjunctive pharmacotherapy to opioids in the management of their cancerrelated neuropathic pain.
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Theoretical Framework
The socioecological framework (SEF) model (Figure 1) conceptualizes the hierarchy of
society, community, interpersonal and individual factors affecting a public health problem. At
the societal level, there are legislative and health policy factors that present barriers or facilitate
access to medical cannabis in local community dispensaries. These policies can create the
environment in which prescribing norms and standards of care operate at the organizational level
within dispensaries and in communities. It is also at this level that one can examine the
mechanisms and processes through which prescribing physicians and treated patients conform to
state policies regarding medicinal marijuana. Stigma and social norms operate at both
community and intrapersonal levels relating to acceptability of pain management options such as
opioids and CBM, wherein the HRQoL measures are used to describe the impact of chronic. At
the individual level, the patients themselves and their experiences are considered.
The goal of this dissertation is to provide current scientific and health perspective data of
medical marijuana to inform the public and build support for its regulated use. The author has
studied marijuana for several years, however the information contained in this dissertation is
only a fraction of what is currently known as it addresses essential gaps in our knowledge. The
study in Chapter 2 explores stakeholders’ lived experiences in multiple downstate New York
dispensaries under the management of Vireo Health, and examining facilitators and barriers of
New York State’s Medical Marijuana Program and the use of CBM as an adjunct to the
treatment of neuropathic pain. There has not been a previous study of the performance of this
Program so it provides meaningful data to this literature gap. The study in Chapter 3 addresses
the cost-effectiveness of adding medical cannabis to opioid analgesic medication in the
management of chronic pain in patients using the example of sickle cell disease. It uses a model
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and decision tree analysis derived from literature assumptions with a limited time horizon and
2017 US$. There has not been a study of this type in sickle cell disease, nor has there been a
study comparing the cost-effectiveness of cannabis-assisted treatment in managing chronic pain
compared to the standard-of-care of opioid pharmacotherapy in various states of opioid addiction
and dependency. With legalized use of medical cannabis, there will be research opportunities to
address opioid addiction in a controlled manner by choosing appropriate disease models such as
sickle cell disease. Hence, the study in Chapter 3 paves the way for addressing this literature gap.
The study in Chapter 4 prospectively explores the lived experiences of individuals with cancerrelated neuropathic pain in a single upstate New York dispensary offering insights into another
spectrum of chronic neuropathic pain disorders due to diverse cancers, which also engender
opioid dependency. However, unlike Chapter 3, this next study addresses the use of cannabisassisted therapy from a qualitative research focus in understanding the lived experiences of a
cohort of subjects with cancer-related pain who use a single marijuana dispensary in upstate New
York. Chapter 5 concludes with the limitations and strengths of the studies and their relevance
for health policy and further addresses the topic of legalization of marijuana nationwide.
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Figure and Legend
Figure 1: The socioecological framework is a multilevel conceptualization of health that includes
intrapersonal, interpersonal, organizational, environmental, and public policy factors.
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Chapter 2: An In-Depth Interview Study of Stakeholders in the New York State
Medical Marijuana Program

Abstract
Background: New York State’s Medical Marijuana Program was launched in 2016
allowing for the sale of medical marijuana products. However, there has not been a review of its
performance.
Objectives: A pilot study examining New York State’s Medical Marijuana Program was
undertaken to assess the experience and gaps in its performance from the standpoint of
dispensary prescribing physicians, dispensary pharmacists, patients, educators and entrepreneurs.
Methods: Semi-structured, in-depth interviews were administered to a cohort of 12
subjects from various locations in the 5 boroughs of New York City and elsewhere in New York
State, including 4 prescribing physicians, 4 pharmacists, 2 patients, 1 educator and entrepreneur.
The data was analyzed using Dedoose for the determination of emergent themes.
Results: Several themes emerged overall and within three distinct areas of the
implementation process for the application and registration process for opening dispensaries, the
registration process for a referring provider and the registration of qualifying patients notably
“effective” and “safe” as facilitators, and “stigma” as a barrier. The code “Safe” identified areas

where participants spoke about the demonstrated safety of marijuana as a medication, which has
shown to be much safer than other legal drugs, including being used to help patients come off
opioids. It was also used to highlight areas where participants noted that legalized versions or the
drug is even safer because they are regulated.
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Discussion: The themes that emerged from the interviews highlight tensions in the
Program. While tightly regulating the process of certification for all stakeholders (physicians,
patients and dispensaries) may be seen as a benefit in regards to providing physician education,
assuring the appropriateness of cannabis products for patients, and mandating dispensary safety
measures, pharmacy consultations, and quality regulation of medications; the bureaucratic
slowness of the process and extra steps were regarded as barriers. These barriers highlight New
York State as being behind the science and actively depriving patients of potentially beneficial
medication. In-depth interviewing has several limitations. This study has several limitations. First, the

results are shaped by the questions asked and influenced by social norms and the participants’
perceptions of what they think the interviewer wants to hear. Further, the personal nature of the
data obtained makes it difficult to replicate findings or to extrapolate generalizable results.
Conclusions: Although New York State’s Program suggests an otherwise simple
straightforward process toward patient receipt of medical cannabis, stakeholders that were
interviewed perceive it is overly medically restricted, fear divulging personal and professional
information to government offices, high cost, and lack of available insurance coverage.
However, there is a perception of safety compared to opioids or the medications that are
presently used to combat addiction: Public health policy guiding New York State’s Medical
Marijuana Program needs to be addressed in a comprehensive manner to reduce barriers to
prescription, cost, stigmatization, and privacy concerns. Socioecological and biopsychological
frameworks may be useful in addressing public and legislative policies associated with the
Program.
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Introduction
Political ideology, conflicting medical evidence and opinions and media attention have
all affected the formulation of public health policy of medical cannabis. However, the US Drug
Enforcement Administration (DEA) continues to list medical cannabis as a Schedule 1 agent
without medical use adds to the difficulty of states’ legislators to implement regulations
governing the dispensation of registered medical cannabis by credentialed health care providers
to patients with certified needs (1-3). The states have regulated medical cannabis differently
concerning the permissible amount an individual can possess. There are also differences in the
pathways for provider, dispensary and patient registration and certification to be eligible for
participation, as are perceptions in its legitimate use that add to the complexity in forming a
unified public health policy surrounding CBM.
The past several decades have witnessed a dramatic increase in societal interest in not
only preventing due to contracting chronic diseases, but in recognizing the importance of social
influences on health and disease. By targeting social and environmental factors, and
interventions directed at changing interpersonal, organizational, community, and public policy,
socio-ecological models have become pivotal in understanding the contribution of society,
community, interpersonal and intrapersonal factors in disease prevention and health promotion.
First noted by McLelroy and colleagues (4), the socioecological framework (SEF) model, which
is in fact a victim-blameless approach to disease according to Tesh and colleagues (5), resonates
well with health policy measures associated with medical cannabis because it sets aside
stigmatization. The implementation of public policy by a system-change approach alone,
according to McLeroy and colleagues (4) is unlikely to succeed in a democratic and pluralistic
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society because it relies on the consent of the governed, failing to take into account the social
causation of illness, and its departure from individuals and their choices.
Qualitative research methods employing semi-structured, in-depth interviews, have been
employed in a socioecological framework and in biopsychological models to help formulate
public health policy in medical cannabis (6) and in improving therapeutic decision making in
adolescent and adult cancer therapy (7, 8) and mitigating chronic pain (9). Among 649 subjects
aged 18 to 34 years, identified through Facebook ads targeting tobacco and marijuana users,
investigators (6) noted that more frequent use of marijuana and greater user friends led to
enhanced motives and less concerns about driving under its influence (R-squared = 0.442). The
authors (6) concluded that interventions and campaigns addressing social norms and risk
perceptions of marijuana use would be successful.
Lamonica and colleagues (10) investigated the process of new policy implementation of
medical cannabis in Massachusetts in 2012, when that state legalized medical marijuana under
Chapter 369 of the Act of the Humanitarian Use of Medical Marijuana statute. They analyzed
qualitative data generated from ethnographic field notes, media reports, public records, and
conducted in-depth interviews with medical marijuana dispensary stakeholders, health care
professionals, and patient consumers, and triangulated their findings with a grounded theory
approach. The investigators (10), noted gaps in transparency, communication, and education in
the transition from illegal to legal status under the Massachusetts statute that governed the
regulations for patients and caregivers, and permitted certification of physicians and the
registration of marijuana dispensary entrepreneurs. Even after the passage of the statute, and
while public policy was being developed and implemented, the task of social reconstruction of
marijuana as medicine (11), was necessary illustrating the social challenges associated with an
37

illegal drug becoming a legal medicine. Social reconstruction theory, as described by Boeri and
Lamonica (11) proposes that most of which passes for knowledge in society is socially
constructed, particularly common sense knowledge that constitutes the reality of everyday life
for most of its ordinary citizens. This has reformed our concepts of marijuana use from early
depictions of illicit mindful behaviors (12) to a more modern view of the intricate
interdependency of social, environmental, and individual biological determinants.
The experience in New York State (NYS) has not been formally studied. In 2016, the
Commissioner of Health of the NYS Department of Health (DOH) certified its Medical
Marijuana Program and delineated rules for registration and certification and prohibitions
associated with health practitioners and facilities, and approved its use for managing the pain and
suffering associated with severe debilitating or life-threatening cancer. Additional regulations
passed in 2017, amending Section 502, Subpart 55-2 of Title 10 of the Public Health Law (PHL),
allowed for the sale of medical marijuana products, providing for an improved experience for
patients and visitors at dispensing facilities, and new courses for prospective practitioners to
complete their training in a shorter amount of time were mandated. There were new forms of
medical marijuana available and improving the dispensing facility experience. Under the new
regulations, registered organizations were allowed to manufacture and distribute additional
products including topical lotions, ointments and patches, as well as solid and semi-solid
products including chewable and effervescent tablets and lozenges. Certain non-smokable forms
of ground plant material were permissible for manufacture and distribution. All products were to
be subject to rigorous testing and the DOH reserved the right to exclude inappropriate products
or those, which pose a threat to the public. In improving the dispensing facility experience, the
new regulations allowed prospective patients and practitioners to speak directly with a registered
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organization representative, learn about products, and get information about the medical
marijuana program. In addition, these measures will allow people other than designated
caregivers to accompany certified patients to the dispensing facility. In refining the training
program for practitioners, the new regulations allowed for a shortened two-hour version of the
present four-hour practitioner's course required to certify patients for medical marijuana.
Other regulatory actions made a number of changes to help enhance the medical
marijuana program including a broadening of the capability of registered dispensaries to
advertise, streamlining the manufacturing requirements for medical marijuana products,
amending security requirements, and clarifying laboratory-testing methods, among other actions.
Five such dispensaries were authorized to manufacture and dispense medical marijuana in NYS
to improve patient access, product pricing and availability and the geographic distribution of
dispensing facilities across the state. As of August 2017, there were 26,561 certified patients and
1,155 registered health practitioners (HP) participating in the program. The number of certified
patients increased by 11,569 (77%) since the addition of chronic pain in late March 2017.

Methods
Approval by the City University of New York (CUNY) School of Public Health (SPH)
Human Research Protection Program was granted to carry out a pilot study examining New York
State’s “Program,” from a convenience sample of subjects recruited by Vireo Health from whom
primary data was collected through via in-depth semi-structured interviews and demographic
questions. The interview instrument employed as shown in Appendix 1 was modified from an
earlier study (6). Each participant gave verbal consent to participate and each interview was no
longer than one hour. A topic guide instrument was developed with major domains of
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stakeholders’ personal views, community norms, attitudes, and behaviors, prescribing practices,
knowledge of drug cost, insurance coverage, and financial subsidies, pharmacy and dispensing
processes of medical marijuana (“cannabis”). Dedoose®, a cross-platform on-line application for
analysis of qualitative and mixed methods research, was used for data analysis. Creating the
codebook was a reiterative process. The process of making notes about themes immediately after
completing each interview was followed by a review of contemporaneous notes, which were
grouped together as similar themes. Then, an initial codebook was compiled from the coding of
transcripts. After completing the first round of coding, another read through of the transcripts
was performed to identify narrative sections that were not captured. A review of the data analysis
outputs resulting from this initial coding was used to identify additional new codes and subthemes.
The new codebook was entered into Dedoose and the transcripts were reviewed using the updated
codebook and additional coding added to comply with the new codebook and definitions. Categorization
and filtering of important themes and coding was an individual process.

Results
Demographics
The study cohort included 12 subjects from various locations generally within the 5
boroughs of New York City (NYC), as well as other areas of NYS, of whom 7 were female, 4
were male, and one participant declined to specify; 4 subjects were pharmacists, 4 were
prescribing providers, 2 were patients, 1 was a patient care coordinator, and 1 was a Medical
Marijuana Educator. All were associated with Vireo Health located in Greater NY and elsewhere
in NYS. We also gathered information regarding ethnicity, education, employment, age, and
political identity, however trends were not contextualized using this data.
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Emergent Themes
Several different themes emerged overall and within three distinct areas of the implementation
process for the application and registration process for opening dispensaries, the registration process for a
referring provider, and the registration of qualifying patients.

The codes that emerged most frequently overall were “Effective” and “Safe” as
facilitators, and “Stigma” as a barrier. The code “Effective” was used when participants were
speaking about the effectiveness of medical marijuana as a medication for various conditions and
how this has been a facilitator for its legalization, acceptance, and use. The code “Safe” was used
to identify areas where participants spoke about the demonstrated safety of marijuana as a
medication, which has shown to be much safer than other legal drugs, including being used to
help patients come off opioids. It was also used to highlight areas where participants noted that
legalized versions or the drug are even safer because they are regulated. The code “Stigma” was
used to highlight areas when participants discussed misperceptions or personal stigmas as a
barrier to legalization, acceptance, and use. It was also of interest to note that many of the
participants that extolled the virtues, effectiveness, and safety of the drug, described those they
personally would be uncomfortable asking for or becoming a medical marijuana patient.

Application and Registration Process for Opening Dispensaries
Themes in both barriers and facilitators to the process for opening dispensaries emerged
from the interviews. Barriers to the process included “Process,” which identified the very
rigorous and competitive state process for applying, registering, and running a dispensary. The
second theme that arose was “Cost,” which included the high amount of capital needed to apply,
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followed by the high overhead needed to continuously meet all the regulations, coupled with the
relatively low revenue. These barriers have resulted in low numbers of dispensary companies and
limited dispensary locations. They have also made the sustainability of the dispensaries as a
business challenging.
There were also some themes that emerged as facilitators for the application and
registration of dispensaries. One such facilitator was actually the regulations themselves. While
the process and cost were seen as barriers to actually opening dispensaries, the various
regulations regarding safety measures and dispensary rules of operation were seen as facilitators
for community acceptance. The regulations that emerged as helpful ranged from the safety
measures and video surveillance that may actually make the surrounding community safer, to
regulations about products available, which do not smell or lend themselves to people hanging
around smoking. A second theme noted as a facilitator for opening dispensaries was job creation.
A number of participants notes that one of the benefits of the opening of dispensaries around NY
would be the jobs that it created in those communities. Joe Dolce noted that this trend is being
seen nationwide, with the number of people working in the cannabis field already surpassing
other ubiquitous fields, such as bakers.

Registration Process for a Referring Provider
Once again, the intensive process was noted as a barrier. This barrier includes the process
of becoming a referring provider and the extra hoops that providers have to go through after they
are registered in order to create a referral for each patient. This process generally included
gaining approval from the place you are employed, taking the class, passing the test, sending
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paperwork to the state, getting registered, learning the recommendation system, opening a
website or telling patients about the options, and then going through the prescribing process with
each patient each time. A second barrier was the education regarding medical marijuana for
providers. Becoming registered requires a 2-hour course be taken; this is reduced from the 4hour course that used to be required. While the reduction in hours does reduce the time
investment needed for a provider to become registered, it was mentioned by many that it was
insufficient. It was also noted that the education on cannabis in Medical School and the available
resources and studies online are also lacking.
A few strong themes emerged as facilitators for registration of providers. This included
new research and personal experiences of patients showing the use of medical marijuana for
treating a number of complaints and conditions more effectively that the current standard of care,
as well as, interesting providers in going through the registration process and being willing to go
through the extra hoops necessary to recommend patients for this treatment. Another motivating
factor for providers is the safety profile of medical marijuana. Many of our participants noted the
minimal side effects compared to current standard drugs. They also highlighted the opioid
epidemic and the potential to save lives with a painkiller with a higher safety profile. While
neither of these facilitators helped facilitate the actual process, they were seen to facilitate the
number of providers becoming registered by increasing motivation and interest.

Registration Process for Qualifying Patients
This study also examined barriers associated with the registration of qualifying patients.
A major barrier noted by all the stakeholders was the process from the patient side, such as
finding a registered provider, bringing documentation of their qualifying condition, having a
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NYS resident ID, registering on the state website, waiting for the card, having a consultation
with a pharmacist. It is quite a bit more effort than patients have to put in for other medications.
Another major barrier is cost. As a federally illegal substance, insurance companies do not
currently cover the cost of the medication, putting the medication out of reach for a large number
of patients that could potentially benefit. Another barrier that emerged was stigma. Patients may
themselves carry stigma towards the drug or may be concerned that others will judge them for
using the medication. Even among our participants who spoke strongly against the stigma
surrounding medical marijuana, they noted that they would be hesitant themselves to register for
a card. Some listed the reason as wanting to promote legitimacy, some indicated that the fact that
it was still federally illegal or that they didn’t know if their medical boards would like it made
them hesitant, and a few seemed to realize during the interview that they were in their own words
“hypocrites” regarding the stigma. The study also highlighted some facilitators associated with
the registration of qualifying patients. One of the facilitators for registration of patients that came
up frequently was legalization itself. The very act of legalizing means that patients are more
likely to consider medical marijuana as a medication. Another big facilitator for patients
becoming registered is education, both the growing understanding of how effective this
medication can be and education about the process for registering. This can be from personal
experience, shared stories of other patients, reports coming out, providers talking about it, but the
more patients hear and learn about the possibilities, and the more they are educated on the
process, the more interested and able they are to navigate the program.
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Code Co-Occurrence
The co-occurrence of themes also highlighted important interactions, for example, cooccurrence was highest for the codes “Safe x Effective.” Both of these were seen as facilitators
for the program, the fact that there is now an option for a relatively effective medication for a
variety of conditions that has a much higher safety profile than many standard of care
medications is a strong support for the program. The next most frequently co-occurring themes
were “Limited Qualifying Conditions” as a barrier to the program and “Effectiveness” of the
medication for many conditions as a facilitator. This tension highlights the theme that arose in
our interviews that New York is being slow to expand the uses of medical marijuana, which may
be doing a severe disservice to patients that could potentially benefit. “Stigma” as a barrier for
use frequently co-occurred with “Education” as a need or as a facilitator for the program,
suggesting that education is the best way to combat stigma and support the program. “Federal
Legalization” was a barrier frequently co-occurred with “Cost” as a barrier, which highlights the
problematic aspects of making medical marijuana legal, and therefore available, in the state of
New York, while failing to make it actually accessible to many patients who could benefit from
it.

Discussion
The themes that emerged from the interviews highlight tensions in the Program. While
tightly regulating the process of certification for all stakeholders (physicians, patients and
dispensaries) may be seen as a benefit in regards to providing physician education, assuring the
appropriateness of cannabis products for patients, and mandating dispensary safety measures,
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pharmacy consultations, and quality regulation of medications; the bureaucratic slowness of the
process and extra steps were regarded as barriers. These barriers highlight New York State as
being behind the science and actively depriving patients of potentially beneficial medication.
These often-mentioned barriers included the onerous registration process for providers and
patients; overly lengthy (10,000-page) application for the dispensaries, and limits placed by New
York State on the number of dispensaries and approved diagnosis.
Although New York State’s Program suggests an otherwise simple straightforward
process toward patient receipt of medical cannabis (Figure 9), stakeholders that were interviewed
suggested otherwise.
Yes, you have to go and do the classes and pass the test, and then send your paperwork to
the state and wait for the approval by the state, and then get registered, and then they’ll figure
the health commerce system. And then start prescribing and open up a website, or tell your
patients what’s going on and convince them that they need it and it’s available to them, and it
will work. And it’s better than everything else. So there’s a lot of hurdles there. Lots and lots and
lots of hurdles (Daley, Physician).
So, it took me until the end of last year to go through the hoops at my work and get them
to give me the okay to get certified and be able to prescribe for our patients. I do feel like my
education in marijuana itself is pretty sorely lacking, and even the required course that I took
was pretty minimal in terms of the amount of information that was available to me, the amount of
information that it was required for me to have in order to prescribe. Even the sources out there
for additional information, just prescribing wise whether it’s a side effect profile, or what
populations would benefit most from it, I still have kind of yet to really feel like I have a good
amount of knowledge on the subject. (Anne, Physician).

Pertinent views of the limitation of access to medical cannabis in New York State were
voiced by other interviewees, including its use in a restricted number of medical condition,
divulging professional information to government offices, high cost, lack of available insurance
coverage, notwithstanding its safety compared to opioids or the medications that are presently
used to combat addiction:
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I know that it is effective with certain conditions. I know that there are many conditions
out there that it is not approved for. And I have seen some really remarkable results with the use
of medical marijuana for sick patients (Lydia, Physician).
So why do they need to create an account with the Health Commerce System at all? Why
can’t we do that as prescribers since we’re doing that for basically everything else? I can order
chemotherapy for somebody and they don’t have to do a thing, but for medical marijuana they
do. There’s a huge step that involves patients, which for every other drug they don’t have to do
that. So I would take away that involvement, because I feel like that’s really limiting people’s
ability to get the medication they need. (Anne, Physician).
Doctors have a new option for pain management and I think that the way that our minds
are changing about opioids, this is going to be a much more useful option and a much more not
only useful option but, for one, it's a safer option. You know we should have fewer opioid deaths
(JC, Pharmacist).
It’s difficult because I’m on disability. So, I only have a limited amount of income. It’s
hard when you have to choose between medication and another necessity of the house because
insurance doesn’t cover medicinal marijuana. So, I don’t understand how the government would
love to pay for opioids to keep me as a zombie, but not my cannabis that makes me productive. I
can’t grasp that idea. (Starr, Patient).
I think, once again, it’s a negative opinion about it. “Oh, you have cannabis, you’re
using medical marijuana.” It’s like, “Oh, we want to avoid it.” And that’s how I think the whole
medical community is in general. We don’t have enough providers giving it. We have more
providers giving Suboxone and the Buprenorphine, and writing opiates than we do have
cannabis. And that shows you right there. In fact, it should be the opposite way. Cannabis should
be first and opiates should be last. But nope, it’s the opposite, so ... We’re all stuck with it.

The socioecologic framework model that places society and health policy at the highest
level, notably stakeholders in policy development, dissemination, enforcement, evaluation and
revision; followed by community factors below, and interpersonal relationships and intrapersonal
factors below appears to be useful in assessing medical marijuana programs state-wide and
probably nationwide. At the societal level, decriminalization remains the greatest obstacle to
destigmatizing medical cannabis. Legalization at the national level should be continued because
it has the potential to reduce barriers posed by high cost and lack of insurance coverage. There is
a need for an expansion of qualifying conditions for medical cannabis, and expansion in the
number of dispensaries. At the community, level of physicians, pharmacists, and entrepreneurs
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there needs to be not only effective education and destigmatization of medical cannabis, but also
supportive networks for sharing information, consistency in prescribing, and the development of
evidence-based algorithms adjusted to diverse patient populations and applicable products. At
the intrapersonal and interpersonal level, qualitative ethnographic studies incorporating the views
of individuals have the potential to provide valuable insights into the lives of patients and their
friends, caregivers and family members. Education that needs to be available and easily
accessible on the uses and effects of medical cannabis marijuana, the location of dispensaries and
their regulations, needs to be racially and historically sensitive, and destigmatizing of its uses,
prescribers, and dispensers.
Although there is no published experience in the biopsychological approach to guide
medical cannabis public policy (13), this approach, which posits that illness and health are the
result of an interaction between biological, psychological, and social factors, has a role to inform
Program public health policy. At a time when healthcare systems designed around acute
biomedical care models are struggling to improve patient-reported outcomes and reduce
healthcare costs, the biopsychological approach should be integrated with the socioecological
framework.
Despite the many strengths of structured, in-depth interviewing, this modality has some
significant weaknesses and limitations in regards to design, implementation, and analysis (14).
First, in-depth interviewing can be difficult. Designing, preparing for, and conducting interviews
take a lot of thought and skill, and as the interviewer is not only the researcher, but also the tool
of data collection, it is important that they have the necessary skills to obtain meaningful data.
Second, data gained during in-depth interviewing may seem overly subjective. However, this
generally reflects the underlying study design, interviewing technique, and data analysis. The
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design of the interview and topic guides are shaped by the questions asked. Third, the responses
are influenced by social norms concerning what can, and should be spoken, and what the
participant thinks the interviewer wants to hear, as well as their perceptions and opinions are at
the time of the interview. Lastingly the personal nature of the data obtained makes it difficult to
replicate findings or to extrapolate generalizable results.
A significant weakness of the study design was the heterogeneity introduced by the
involvement of more than one medical cannabis dispensary, which led to a greater geographic
diversity of subjects; and we did not contextualize demographic data to ascertain trends. The
latter may be useful to carry out in future studies.

Conclusions
Viewed through the lens of the real-time perspectives of dispensary entrepreneurs, health
care professionals, and patients, it is possible to clarify the actors and social and environmental
factors, and gaps in health policy relevant to the success of New York State’s Medical Marijuana
Program. With an increasing proportion of healthcare resources devoted to chronic disorders and
the accompanying need to improve patient outcomes, a biopsychological approach should be
integrated into future Program policies guiding medical cannabis for the diverse chronic illness
for which it is approved.
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Chapter 3: A Cost Effectiveness Analysis of the Treatment of Sickle Cell DiseaseRelated Neuropathic Pain with Medical Cannabis

Abstract
Background: Opioid analgesic drugs have the propensity for both abuse and medicinal
use. These drugs have fueled the opioid epidemic, posing a significant public health burden for
patients who are addicted to, and develop tolerance to them. Despite their serious side effects,
including tolerance and addiction, opioids remain the standard of care for treating chronic pain in
patients with sickle cell disease. Medical cannabis provides analgesia through its action on
endocannabinoid receptors in the nervous system and may serve as an effective means of
managing chronic pain by mitigating the side effects associated with opioid treatment. We
sought to evaluate the cost-effectiveness of treating chronic pain in sickle cell disease patients
with medical cannabis compared to opioids alone.
Objective: To evaluate the cost effectiveness of adding medical cannabis to opioid
analgesic medication in the management of chronic pain in patients with sickle cell disease
between crises.
Methods: A cost-effectiveness analysis was performed using a decision tree in TreeAge
Pro to simulate the cost and clinical outcomes of adding medical cannabis treatment for chronic
sickle cell disease pain compared to the standard of care using opioid analgesic medication
alone. Probabilities, costs, and quality of life utility weights associated with opioid use and
chronic pain among patients treated with medical cannabis versus standard of care are derived
from published literature. Primary outcomes included medication costs and health-related quality
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of life (measured in adjusted life years, QALYs). The analysis was carried out from a healthcare
sector perspective with a time horizon of one year. Medication costs associated with chronic pain
treatment involving cannabis and opioids expressed in 2017 US dollars. Incremental costeffectiveness ratios were calculated by comparing cannabis-assisted treatment with opioid-only
standard of care. One-way sensitivity analyses and threshold analyses were performed to assess
parameter uncertainty.
Results: Cannabis-assisted treatment is estimated to reduce addiction by 11.5% among
SCD patients previously addicted to opioids and improve chronic pain control from 56% to 76%.
On average, cannabis-assisted treatment increased monthly pain management medication costs
by $1781.21 per person compared to opioid analgesic treatment alone ($6037.61 vs. $4,256.40)
and produced 0.06 more QALYs per person (0.58 vs. 0.52 QALYs). The resulting incremental
cost-effectiveness ratio was $27,219.78/QALY gained. Based on a commonly used
$100,000/QALY willingness-to-pay threshold, cannabis-assisted treatment was very costeffective compared to the opioid-only strategy. Sensitivity analyses suggested that these results
were robust against a wide range of parameter values.
Conclusion: The use of medical cannabis for chronic pain management in patients with
sickle cell disease is likely to be a cost-effective intervention when compared to the current
standard of care of opioid analgesics alone. With the increasing availability of medical cannabis
from dispensaries to treat chronic pain, it may be advantageous to integrate medical cannabis
into the multidisciplinary management of sickle cell disease pain.
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Introduction
Opioid analgesic drugs, often referred to as “opioids” or “narcotics” with the propensity
for both abuse and medicinal use, have fueled the acronym “opioid epidemic”, posing a
significant public health burden (1). According to the United Nations Office on Drugs and
Crime (2), an estimated 3% to 6% of the world’s population aged 15 to 64 years, or
approximately 250 million persons, consumed an illicit drug in the past year. According to the
National Survey on Drug Use and Health (3), of the 22.6 million persons in the United States
aged 12 years or more who used illicit drugs in 2012, 22.5% used opioid analgesic drugs, lagging
behind marijuana. Early opioid prescribing patterns are associated with long-term use. While
patient characteristics are important, clinicians have the greatest control over initial
prescribing.(3). Patients who may divert or abuse them complicate the long-term prescribing of
opioid analgesic drugs.
One particular disorder, sickle cell disease (SCD) is characterized by painful vasoocclusive crises and is largely managed with opioid analgesic drugs to date (4, 5). Pain in SCD
patients between and during crises (6) severely affects individuals' quality of life (QoL).
Nonetheless, many healthcare providers are reluctant to prescribe opioid analgesic medication
for SCD patients, citing concerns around the credibility of self-reported pain, and the risk for
physical dependence, tolerance, and addiction. These concerns are similar to other clinical
situations involving chronic, non-malignant pain (7). Adults who self-medicate with marijuana
appear to derive the beneficial effects of the endocannabinoid system on opioid receptors to
mitigate pain (8) supporting the potential role of medical cannabis in the multidisciplinary
management of SCD pain. One qualitative study of adults living with SCD found that marijuana
was the commonest non-opioid pharmacologic approach used in conjunction with opioids (9).
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There has not been a formal cost effectiveness analyses (CEA) on the use of medical cannabis in
conjunction with opioid analgesics in SCD pain management.
As a disease typified by both acute and chronic pain, SCD provides relevant examples for
exploring the challenge of balancing the burden of patients suffering from pain with the risks of
opioid dependence and abuse. An estimated 100,000 individuals have SCD in the United States,
with 2,000 new cases detected annually through newborn screenings (10). Affected individuals
have atypical hemoglobin molecules that obstruct vessels leading to painful vaso-occlusive crises
(VOC) in the bones, lungs, brain, kidneys and spleen tissues. Self-reported pain in SCD between
and during crises severely compromises individuals’ quality of life (QoL). Advancements in the
science and treatment of this disease have transformed SCD from a childhood illness, to a
chronic disease of adulthood. Across the age span there can be a more complex pain syndrome
caused by dysfunction of the nervous system due to underlying neuropathic mechanisms (11).
Opioid analgesics are used to both treat acute pain crises and to manage chronic pain.
However, patients who experience severe chronic pain are typically prescribed higher baseline
doses of opioid analgesic medications, which results in increased tolerance to opioids. Such
practice blunts the analgesic response of opioids making acute painful crises even more difficult
to manage. Higher baseline opioid dose for chronic pain management correlates with high levels
of emergency room (ER) utilization and poor pain control of acute pain crises (12). Further,
high-dose opioids are associated with the risk of overdose. Several patient characteristics
associated with an elevated risk of opioid overdose include a history thereof, and addiction to
any substance (but particularly alcohol, benzodiazepines, and opioids). The presence of renal or
hepatic dysfunction also increases the risk of overdose, since the clearance of opioid drugs is
impaired in patients with either of these conditions, which leads to higher and longer-lasting drug
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levels in the blood. Finally, because some cases of overdose may be purposeful suicide attempts,
a history of suicidal thoughts or attempts and a diagnosis of major depression also increase the
risk of overdose.
The opioid epidemic and stigma related to opioid use contribute to an under treatment of
SCD pain. Research has found negative attitudes towards patients with SCD by health care
providers reluctant to prescribe opioid analgesic drugs (7). Pain experienced by SCD patients
remains largely undertreated, in part due to disparities in analgesic administration by healthcare
providers. The Pain in Sickle Cell Epidemiology Study found that adults self-reported pain in
54% of the days surveyed (13), making daily pain a constant worry among SCD patients.
Beyond individual suffering, the management of SCD complications represents major healthcare
utilization and accounts for a disproportionate amount of medical costs. For example, by age 45,
a patient with SCD will likely accrue $900,000 in undiscounted medical expenses, and use an
excess of inpatient and outpatient hospital services, especially ER use for pain management.
In SCD, the trend of declining QALYs begins in childhood. Young adults with chronic
pain who are physically and psychologically debilitated present healthcare providers with the
challenge to implement complex medication regimens by reducing opioid analgesic pain
requirements, leading to the reliance on emergency room (ER) rather than ambulatory center
care. Coupling the lack of evidence for optimal chronic pain management in SCD with a
majority of patients prescribed opioids who may not abuse or misuse them; there remains a
critical need for better pain management options. This is evident in the challenge to manage the
complicated pain profiles of SCD patients, their impact on health service usage and reduced QoL
of life.
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This study addresses the cost effectiveness of adding medical cannabis to the
pharmacologic regimen of oral opioid analgesic medication in the management of chronic pain
in SCD patients between crises.

Methods
A decision analysis was conducted to estimate the costs and clinical outcomes of two
SCD pain management strategies: (1) incorporating medical cannabis and (2) standard of care
with opioid analgesic treatment alone. The decision tree included the prevalence of opioid
addiction (20% among SCD patients), the probability of reducing opioid dose among SCD
patients with opioid addiction (11% when supplemented with cannabis), and the various degrees
of achieving adequate control under the two strategies (76% under combination therapy vs. 56%
under standard care). These base case assumptions and the sources of data inputs are summarized
in Table 1.
Outcome: The main clinical outcome measure is the expected value of quality-adjusted
life year (QALY) derived from health-related quality of life (HRQoL), which refers to the way
an illness affects one’s ability to live pain-free, work productively, and interact with family. It is
expressed as a”utility weight”, a number between zero and 1, with 1 representing perfect health,
0 typically representing death, and those with disabling chronic disease a fraction thereof (14).
QUALY expresses the proportion of time lived in perfect health, and is calculated by multiplying
HRQoL by the number of years of remaining lifespan. Addiction and chronic pain diminish selfreported overall HRQoL in SCD (15). In SCD, the trend of declining HRQoL begins in
childhood and continues through adulthood (12). Based on self-reported effects of body pain on
57

physical functioning, behavior, general health, and self-esteem, mean HRQoL scores among
SCD patients were comparable to those newly treated for cancer and rheumatoid arthritis (16).
Model Structure and Probabilities: The decision analytic model compared the expected
cost and clinical outcomes of two chronic pain management strategies: Cannabis assisted
treatment and Opioid-only Standard of Care. The decision tree, as depicted in Figure 1,
represented six possible health outcome states: (1) sustained chronic pain and no opioid
addiction; (2) sustained chronic pain and opioid addiction; (3) Opioid-controlled chronic pain
and no opioid addiction; (4) Opioid-controlled chronic pained and opioid addiction; (5)
Cannabis-controlled chronic pain and no opioid addiction; and (6) Cannabis-controlled chronic
pain and opioid addiction .Each health state was assigned a HRQoL utility value, as well as
estimated annual medication costs based on the best available literature searched in PubMed
(Table 1). The model was constructed and analyzed using TreeAge Pro 2018.
Analysis: The analysis was performed from a healthcare sector perspective. The analysis
time horizon was one year. Medication costs associated with SCD chronic pain treatment
involving cannabis and opioids were assessed within the decision model and expressed in 2017
US$. Medication costs were collected from a metropolitan New York City medical cannabis
dispensary (Vireo Health) and the literature. Given the one-year time horizon, no discount rate
was applied. The healthcare perspective of the analyses was limited to medication costs. Other
SCD management costs unrelated to pain control were assumed to be the same under the two
strategies compared (hence omitted in the incremental cost-effectiveness analysis). Model input
parameters were derived from published literature and summarized in Table 1.
The incremental cost-effectiveness ratio (ICER) was calculated by dividing the
incremental cost of medication by the incremental gain in QALY derived from cannabis-assisted
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treatment, compared with standard care. The resulting “base case” ICER was compared to
commonly used willingness-to-pay thresholds (i.e, in the US, $100K per QALY gained). Oneway sensitivity analyses were performed to assess the impact of uncertainty around each input
parameters on the base case conclusion. In these analyses, the model recalculated ICER by
varying one parameter at a time across a range of plausible values (Table 2). Plausible values
were based on the literature and my clinical judgement. For selected parameters with no value
within the plausible range that altered the cost-effectiveness result (i.e., making a cost-effective
strategy in the base case not cost-effective), additional threshold analyses were performed to
determine the parameter value necessary to alter the base case conclusion (17).

Results
Among SCD patients addicted to opioids at baseline (20% of all SCD patients), 11.5% of
them were expected to reduce opioid use, which represented a net 2.3% reduction in the
population suffering from opioid addiction (or 23 out of 1000 SCD patients). In addition,
cannabis-assisted treatment was estimated to result in a greater proportion of patients achieving
adequate chronic pain control. For every 1000 patients, cannabis-assisted treatment was expected
to result in 200 fewer patients suffering from uncontrolled chronic pain (as a result of increasing
adequate control from 56% under standard care to 76% under cannabis-assisted treatment). The
cost of adding medical cannabis to the pain management regimen would incur $242 per patient
per month, but the strategy reduced the cost of opioid treatment from $354.7 to $241 per month,
except for those who remained addicted to high-dose opioids. Overall, the cannabis-assisted
treatment strategy was associated with an incremental cost of $1781.21 per person a year
compared to the standard of care of opioid analgesic treatment alone ($6037.61 vs. $4,256.40).
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Largely because of higher HRQoL among SCD patients with adequately controlled pain, the
cannabis-assisted treatment strategy also produced an average of 0.06 more QALYs per person
(0.58 vs. 0.52 QALYs). The resulting incremental cost-effectiveness ratio (ICER) was
$27,219.78/QALY gained, substantially lower than the commonly used $100,000/QALY
willingness to pay threshold. According to these results, the cannabis-assisted treatment strategy
was considered very cost-effective compared to the opioid-only strategy (Table 2).
In sensitivity analyses, the model was robust across plausible ranges. At a willingness-topay threshold of $100K/QALY, the model outcome was sensitive to the health utility of reduced
pain for cannabis and opioid treatments. Opioid treatment would be more cost effective than
cannabis-assisted treatment when the utility of chronic pain under its control decreased from the
baseline of 0.65 to 0.59, or if opioid treatment increased the health utility of chronic pain on
treatment to 0.69 from the baseline of 0.60. In threshold analyses performed over a wide range
against a willingness-to-pay threshold of $100K/QALY, cannabis-assisted treatment would no
longer be cost-effective when the probability of responding to cannabis treatment was reduced to
0.48 from 0.76, or when the cost of medical cannabis treatment increased from $242 to $639 per
month. Sensitivity analyses are shown in Table 3 for key input parameters.

Discussion
This analysis demonstrates that the use of medical cannabis for the treatment of chronic
pain in patients with SCD is likely to be a cost-saving intervention when compared to the current
standard of care of using opioid analgesics to treat chronic pain. As epidemics require a
paradigm shift in thinking about all possible solutions, the rapidly changing sociopolitical
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marijuana landscape provides a foundation for the therapeutic development of medicinal
cannabinoid formulations to address the current opioid abuse crisis in the United States and in
particular in opioid-dependent patients with SCD (18). There are gaps in understanding the types
of pain in SCD patients, how it changes over the life course, and the best practices for optimal
management. Moreover, the mechanisms of acute and chronic pain in SCD patients are poorly
understood making management of pain a complex issue. While this lack of knowledge impedes
progress toward novel treatments and management tools, our study nonetheless provides
rationale for the use of medical cannabis to reduce cost and increase HRQoL in SCD patients.
This is consistent with the experience of interventional management strategies in SCD that show
up to a 37% decrease in intravenous opioid use (p = 0.02) and 10% decrease in oral opioid use (p
= 0.04) among high-utilizing adults with SCD when multifaceted strategies for pain management
are employed (19).
The only published CEA (20) addressing the use of medical cannabis in the treatment of
neuropathic pain in the US marketplace used a Markov model comparing conventional therapies
for painful diabetic neuropathy modified to include arms for augmenting first-line, second-line
(if first-line failed), or third-line (if first- and second-line failed) therapies with smoked cannabis.
Microsimulation of 1,000,000 patients compared the cost (2017 U.S. dollars) and effectiveness
(QALYs) of usual care with and without adjunctive cannabis using a composite of third party
and out-of-pocket costs. Model efficacy inputs for cannabis were adapted from clinical trial data.
Adverse event rates were derived from a prospective study of cannabis for chronic noncancerous
pain and applied to probability inputs for conventional therapies. Cannabis cost was derived from
retail market pricing. Parameter uncertainty was addressed with one-way and probabilistic
sensitivity analysis. Adding cannabis to first-line therapy was incrementally less effective and
61

costlier than adding cannabis to second-line and third-line therapies. Third-line adjunctive
cannabis was subject to extended dominance, that is, the second-line strategy was more effective
with a more favorable incremental cost-effectiveness ratio of $48,594 per QALY gained, and
therefore, third-line adjunctive cannabis was not as cost-effective. At a modest willingness-topay threshold of $100,000/QALY gained, second-line adjunctive cannabis was the strategy most
likely to be cost-effective. However, a limitation of that study was the limited scope of published
clinical trials, as in SCD-related pain, of pain of cannabis, so the authors derived cannabis
efficacy parameters from participants with human immunodeficiency virus (HIV) neuropathy.
There was evidence in the literature to suggest that this is a reasonable extrapolation: pain relief
from standard therapy agents is similar in HIV neuropathy and painful diabetic neuropathy,
treatment guidelines for both recommend standard therapy agents as first- or second-line agents,
and short-term effects of cannabis for diabetic pain are consistent with effects observed in trials
on HIV neuropathy (21).
This study had the notable strength of applying the CEA comparing medical cannabis to
opioid medication for which the latter is medically and socially acceptable across the age
spectrum and carefully monitored by prescribing physicians. In that regard, there is a reduced
potential for abuse.
This study had three notable limitations. First, the analyses did not include financial costs
associated with non-chronic pain SCD-related healthcare costs, or healthcare costs of opioid
overdose and addiction treatment.
Second, the analyses did not include potential societal costs associated with opioid
addiction including productivity loss and costs incurred in the criminal justice system. The
inclusion of these costs would likely have further improved the favorable cost-effectiveness of
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medical cannabis treatment. However, this would have to be balanced with other societal costs
imposed by cannabis such as impaired driving, presenteeism, or the possibly of marijuana being
a gateway to use of other illicit drugs. Although most people have opportunities to try marijuana
even before they have the opportunity to use harder drugs, it is not necessary to postulate
causality since use of both substances could be a manifestation of the same personality trait.
Third, the effectiveness of medical cannabis treatment for chronic pain in patients with
SCD was not available, thus the effectiveness of medical cannabis on other types of chronic pain
(i.e. diabetic neuropathy) was used as a surrogate, which may not be representative of its true
effectiveness in SCD patients. However, as further studies are performed in the study of chronic
pain in SCD, the sensitivity analyses in this study can be used to estimate whether medical
cannabis treatment is sufficiently effective to be cost-effective.
Conclusion
Medical cannabis provides cost savings and HRQoL benefits in patients with SCD who
are already taking the standard of care employing opioid analgesic medications for pain relief.
With legalization of marijuana-derived pharmaceuticals for medical use, there is an opportunity
for integrating medical cannabis into the multidisciplinary integrated management of SCD pain.
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Figure Legends
Figure 1A, B. Decision tree for analyzing the cost-effectiveness of cannabis-assisted treatment
vs. opioid-only standard care. The decision trees depict two chronic pain management strategies
for patients with sickle cell disease (SCD): cannabis-assisted treatment (“Cannabis”) vs. opioidonly standard of care (“Opioid only”). At baseline, 20% of SCD patients suffer from opioid
addiction. Among these patients, 11.46% (“pReduce”) reduce their opioid use cannabis-assisted
treatment and lower their monthly prescription cost associated with opioids (from cRx_Addict,
$354.7, to cRx_LessOp, $241). The average monthly cost of cannabis (cRx_can) is $242.
Regardless of addiction status, cannabis-assisted treatment increases the probability of achieving
adequate chronic pain control (“Reduced chronic pain”, pPainreduced) to 76%, compared to 56%
in the opioid-only arm. The HRQoL weights associated with each outcome depends on the
presence of persistent chronic pain (uChronic Pain vs. uPainreduced) and addiction to opioid
(uAddicted_dec, expressed as a decrement).
Notations: □Decision node (strategies compared); ○ Chance node (probabilistic events);
◄:Terminal node (outcome health states)
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Figure 2. Two-way sensitivity analysis: Utility of reduced pain with cannabis-assisted treatment
vs. opioids. The graph demonstrates how the cost-effectiveness result depends on the values of
the utility of reduced chronic pain with cannabis-assisted treatment (uPainreduced_can) and the
utility of reduced chronic pain with opioid-only treatment (uPainreduced_op). Generally,
cannabis-assisted treatment is more cost-effective when the quality of life (utility) of reduced
chronic pain under cannabis is higher while the corresponding utility under opioid is lower.
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Figure 1A. Model Structure.
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Figure 1B. Model structure with probabilities and expected outcome values.
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Figure 2. Two-way sensitivity analysis: Utility of reduced pain with cannabis-assisted treatment vs. opioids.
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Table 1. Model Inputs

Input

Value

Reference

Probabilities

Percent of SCD population addicted to
opiates

20%

22

Probability that chronic pain is reduced by
cannabis

0.76

23

Probability that chronic pain is reduced by
opioids

0.56

24

Probability that addiction is reduced by
cannabis

0.1146

25

Probability that addiction is reduced by
opioids

0

Assumption

HRQoL weight/Utility

Decrement from opioid addiction

0.15

25

Chronic pain from SCD

0.48

23

Cannabis-controlled chronic pain

0.65

23

72

Opioid-controlled chronic pain

0.60

26

$242

27

Monthly opioid prescription cost-opioids
only

$354.70

28

Monthly opioid prescription cost under
reduced opioid dose when supplemented
with cannabis

$241

28

Costs (2017 $US)

Monthly cannabis prescription cost

Abbreviations: SCD, sickle cell disease; US, United States; $, dollars.

Table 2. Cost Effectiveness Analysis Result

Opioid
Treatment

Total Costs

Total
QALYs

Incremental
cost ($)

Incremental
Effectivenes
s (QALY)

ICER
($/QALY)

$4,256.40

0.52

-

-

-

$6037.61

0.58

$1781.21

0.07

$27,220

(Standard
Care)

Cannabis
Treatment

Abbreviations: QALYs, quality adjusted life years, ICER, incremental cost-effectiveness ratios.
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Table 3.Sensitivity Analysis
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Input

Range

Outcome (threshold
$100k/QALY
gained)

Value needed to
change outcome
(even if outside of
plausible range)

% of population
addicted

0 to 100

Does not change

Not possible

Probability of reduced
addiction with cannabis

0 to 0.25

Does not change

Not possible

Probability of
responding to cannabis
treatment

0.5 to 1.0

Does not change

0.48

Probability of
responding to opioidonly treatment

0.4 to 0.8

Does not change

0.96

Cost of cannabis
(monthly)

$25 to $500

Does not change

$639

Cost of opioids
(monthly)

$25 to $500

Does not change

Not possible

Utility decrement of
addiction

0 to 0.5

Does not change

Not possible

Utility of reduced pain
with cannabis-assisted
treatment

0.5 to 0.8

Threshold exists

0.59

74

Utility of reduced pain
with opioid-only
treatment

0.5 to 0.8

Threshold exists

0.69

Abbreviations: QALY, quality adjusted life year.
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Chapter 4: The Analgesic Benefits of Medical Cannabis for Cancer-Related
Neuropathic Pain
Abstract
Background: Cannabis-based medications have been employed to reduce physician and
patient reliance on opioid pharmacotherapy for neuropathic pain. One particular condition that is
a legitimate use of medical cannabis is cancer-related neuropathic pain both as an effective
treatment to diminish the need for opioid use.
Objective: To study the usefulness of cannabis-based medication as an alternative or
adjunctive agent to traditional opioid analgesic pharmacotherapy in the management of cancerrelated neuropathic pain in a pilot group of patients residing in an upstate community of New
York State subserved by a single medical marijuana dispensary.
Methods: Twenty subjects with cancer-related neuropathic pain from a single medical
cannabis dispensary in upstate New York met eligibility criteria for study inclusion: age 18 years
or older, English speaking, and cancer-related neuropathic pain to engage in in-depth interviews
of their lived experiences with cannabis-based and opioids analgesic pharmacotherapy in a crosssectional observational cohort study. The dispensary pharmacist recorded demographic data,
dosages and costs of these two medications. The coronavirus disease 2019 outbreak prompted
premature conclusion of data collection. The level of pain at entry was ascertained using a
computed score based on the average of graded interference with enjoyment and general
activities, and a visual analog scale, respectively scored none to worst (0 to 10, and 0 to 5).
Results: There 8 men and 12 women of mean age 59.5 years with cancer-related
neuropathic pain. All 20 subjects were assigned a cannabis-based medication in the form of oral
(7 subjects), sublingual (2 subjects), inhaled (4 subjects) products alone, or in combination (7
76

77subjects). Opioids were taken at entry in 16 subjects. The level of neuropathic pain was
ascertained at entry in 7 subjects as 5.7 via graded interference with enjoyment and general
activities, and 4.25 via the visual analog scale. The employment status was known in 18 subjects,
14 of whom were not working due to disease disability (8 subjects) or retirement (6 subjects)
while 4 others were working full-time (3 subjects) or part-time (1 subject). Subjects live with
pain and discomfort that ultimately affects their quality of life.
Emergent themes relate to experiences of cancer and its treatment, perceptions and
experiences of pain management strategies, perceived benefits of medical cannabis, enablers of
improved pain management, and barriers to pain management. Results highlighted the widely
variable experiences with cancer, cancer treatments, pain management strategies, and their
impact on pain levels and quality of life both between and within individual experiences.
Benefits of using cannabis-based medication in addition to, or as a replacement for, opioid
medicines included the improved safety profile of cannabis-based medication, the improved
flexibility and control subjects had for managing their variable pain, and the reduced dependency
on opioids and other medications. Reported enablers of improved pain management strategies
included the moral, financial and logistical support of family, friends and employers, health
providers that were knowledgeable about cannabis-based medication, and personal exposure and
awareness about cannabis-based medication. The major barriers highlighted challenges resulting
from the lack of full integration into the current health systems such as inconsistent guidance and
access, and financial costs.
Discussion: Cannabis-based medications are effective pharmacotherapy in the treatment
of cancer-related neuropathic pain and useful adjuncts in tapering or reducing the need for opioid
pharmacotherapy with much fewer side effects.
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Conclusion: Cannabis-based medications played an essential role in the management of
cancer-related neuropathic pain in a small cross-sectional cohort both as an alternative and
adjunctive agent to traditional opioid analgesic pharmacotherapy. Future randomized control
studies are needed to confirm the efficacy of cannabis-based medications in the treatment of
cancer-related neuropathic pain and as an adjunctive agent to reduce reliance on opioid analgesic
medications.

Introduction
There is an urgency to integrate CBM into the multidisciplinary approach to pain
especially cancer-related neuropathic pain. Cancer pain results from inflammation, mechanical
invasion of bone or other pain-sensitive structures, and nerve injury. It is severe, persistent, and
often refractory to treatment with opioid-based medications or “opioids.” It is one of the most
common symptoms in cancer patients, especially in advanced disease. It occurs in a significant
proportion of patients during diagnostic and therapeutic procedures, and in some, pain may be
the first symptom of cancer. The causes of pain in cancer patients are often multifactorial
including direct and indirect cancer effects, anticancer therapy and co-morbidities. Moreover,
pain in cancer patients has mixed pathophysiology including both nociceptive and neuropathic
components, especially in patients with bone metastases. Recognition of pain and its appropriate
assessment and treatment may significantly improve patients and families' quality of life (QoL)
(1, 2).
The proposed research sought to ascertain the usefulness of cannabis-based medication
(CBM) as an alternative or adjunctive agent to traditional opioid analgesic pharmacotherapy in
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the management of cancer-related neuropathic pain in a pilot group of patients subserved by a
single medical marijuana dispensary in upstate New York.

Methods
This study was granted ethical clearance by the University Integrated Institutional
Review Board in accordance with the City University of New York Human Research Protection
Program (CUNY HRPP) procedures. Data collection was conducted between January and March
2020.
Study Design: This cross-sectional observational cohort study was designed to document
the lived experiences and management of cancer-related neuropathic pain employing CBM in a
convenience sample of 20 subjects served by a single upstate Vireo Health marijuana dispensary
in Binghamton, New York via in-depth semi-structured phone interviews. De-identified,
routinely collected demographic and quantitative data including cannabis and opioid-based
medications and other analgesic medication was shared by the dispensary.
Design of Research Tools: A topic guide of key themes was developed focusing on the
experience of cancer and its treatment, perceptions and experiences of pain management
strategies, perceived benefits of medical cannabis, enablers of improved pain management, and
barriers to pain management, and formed the basis for the design of the semi-structured, in-depth
interview tool, allowing for the interviews to be largely patient driven while ensuring that the key
themes were addressed in each interview. Specific probes were reviewed and refined during the
study in an iterative process. The interview instrument is shown in Appendix 2.
Scoring Pain: Subjects were electively scored for pain intensity at registration at the
dispensary using a computed score based on the average of graded interference with enjoyment
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and general activities (PEG) scale scored none to worst (0 to 10); and a visual analog scale
(VAS) shown in Appendix 3. The PEG score was calculated from the sum of averages of pain
intensity (P), interference with enjoyment of life (E) and interference with general activity (G).
The VAS was an ordinal facial recognition scale scored none to worst (0 to 5).
Study Site: Data was collected from among clients of the Upstate medical dispensary that
provides pharmaceuticals and follows the needs of clients referred by a physician. The research
site was chosen in collaboration with Vireo for two primary reasons; 1) the area was identified as
an under-researched location with no previous research studies having been conducted here, and
2) the availability of a sizable and receptive population of eligible clients accessing this
dispensary.
Participants and Recruitment: Study participants were selected using purposive, nonprobability sampling. Vireo clients and caregivers of clients with cancer diagnoses attending the
Upstate dispensary meeting the following criteria were eligible to participate: 1.) age >= 21
years; 2.) English speaking; 3.) under care of a referring pain management provider; 4.) not
currently pregnant or breast-feeding. The investigator (DSY) for enrolment in the study
contacted participants who met the eligibility requirements were recruited by the lead pharmacist
at the dispensary, and, after giving permission. In total, 20 participants were included in the
study.
Consent: As the study was conducted over the phone, oral consent was obtained from all
participants prior to commencing with the data collection. A full explanation of the study,
participation, confidentiality and risks was provided to participants. Participants were asked to
provide consent for both the audio recording of the phone interview and for participation in the
research. Oral consent was asked for again after the audio recording device was turned on to
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have a recording of given consent. The contact details for CUNY HRRP were provided to each
participant and copies of the consent form were made available for participants upon request.
Participants were advised that they would not suffer any adverse consequences in their
relationship to Vireo Health if they decided to withdraw from the study.
Data Management: Participant names were not used during the interviews and audio files
of each interview are stored with strong, ZIP-compatible Advanced Encryption Standard (AES)
password protected devices under a participant ID number. Identifying data was removed during
the transcription process and soft copies of the transcripts were saved under participant ID
numbers on a password-protected device. De-identified quantitative data were stored on a
password-protected device. All data will be retained for three years after the study and then
destroyed.
Analysis: The analysis of the qualitative data was conducted using thematic analysis.
Dominant themes emerging from the interview were identified through systematic review.
Salient concepts were coded, and their occurrence and recurrence labelled by hand using
Microsoft Word. Coded excerpts were copied into a themes matrix in Excel where emerging
trends were critically analyzed according to the study aims.

Results
Subject Characteristics: Table 1 lists the characteristics of the 20 study subjects. There 8
men and 12 woman of mean age 59.5 years with cancer-related neuropathic pain associated with
lymphoproliferative tumors (acute myeloid leukemia, Waldenstrom macroglobulinemia, multiple
myeloma, and lymphocytic lymphoma), and malignant cancer of the breast, lung, ovary, prostate,
gallbladder, and skin. Two patients each with lung or prostate cancer had an earlier breast cancer.
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The tumor type was not available in 2 subjects. All 20 subjects were assigned a CBM including
in the form of oral (7 subjects), sublingual (2 subjects), inhaled (4 subjects), or in combination (7
subjects). Opioids were taken at entry in 16 subjects. The level of neuropathic pain was
ascertained at entry in 7 subjects with a mean PEG and VAS score of 5.7/10 and 4.25/5
consistent with severe neuropathic pain. The employment status was known in 18 subjects, 14 of
whom were not working due to disease disability (8 subjects) or retirement (6 subjects) while 4
others were working full-time (3 subjects) or part-time (1 subject).

Emergent Themes
Experiences of cancer and treatment
Subjects live with pain and discomfort that ultimately affects their QoL. Participants
described a range of cancer and treatment experiences, from quick and straightforward
procedures that left them cancer free, to complex, life-long battles with the effects of both cancer
and the treatments. Pain and discomfort not only ranged from minimal to excruciating but
included many forms of pain from dull aches, locked up muscles, acute stabbing sensations, bone
pain, nerve damage, restless limbs, heaviness, stomach pain, neuropathy, etc. The types and
intensity of pain not only varied between patients but also within patient experiences. As one
participant explained:
This week was a good week, and then the next week comes around and all of a sudden,
you’ve got three or four new things you’ve got to deal with (Subject 5).
Changing patterns of symptoms and pain was a common theme among subjects
throughout the evolutions of their cancer and treatments, creating challenges for effective pain
management strategies.
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The sources of subjects’ pain and discomfort also varied. While many of the participants
described feeling no symptoms from the cancer itself, seven indicated that the cancer and the
effects of the cancer in their body caused pain. Fourteen of the study participants described pain
and discomfort resulting from the treatments they were on for the cancer including
chemotherapy, forms of radiation, surgeries, and various injections. The responses to the various
forms of treatment varied significantly between participants. For example, among those
undertaking some form of chemotherapy, subject experiences ranged from minimal impact to
side effects so severe that the chemotherapy treatments had to be halted. As one participant
related:
They were going to have me do chemo the whole summer, but they said no, because it
affected me so bad. I said I don't want to do this. If it's going to kill me before the cancer does
(Subject 8).
The effect that cancer and cancer management has on participants lives is manifold,
affecting participants’ mental health, work, social lives, and ability to perform daily tasks. Study
subjects described intensive routines with multiple visits to various health centers and doctors’
offices per week. They navigated advice, sometimes conflicting, from multiple different doctors
and specialists comprising their health care team. Managing this schedule, particularly when
feeling ill or in pain, is frequently described among participants as stressful in and of itself. This
is particularly true when some of those visits for treatment are known to be the source of
additional pain and discomfort as evident in the comment:
I was always trying to manage everything, and I still had a lot of nausea. It was making
things very stressful for me. To the effect where I would be extremely scared about three days
before I would go in for the next dose (Subject 17).
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Beyond this, the uncertainty regarding outcomes and ability to mitigate and manage
symptoms created additional anxiety and depression. The pain itself was described as a source of
anxiety and depression:
I felt depressed because I thought I was going to die. I felt sad I was leaving my
grandkids. It wasn’t depression, it was just like ‘aw shit, now I gotta die.’ And then you think,
‘well, I’m pretty old anyway.’ I felt like that during the times when it hurt so much and I would
be in bed just in pain and thinking ‘well, maybe it’s better to die.’ And then when I started
feeling well, I was happy again. Happy I could do things and that the pain was gone (Subject 6).
At a time when patients are facing high levels of anxiety, their physical condition also
disrupts their normal support structures in routines. Work is a huge aspect of many people’s lives
and that was reflected in the discussions about the ways in which cancer had impacted the
subject's quality of life. While six of the research participants were retired at the time of the
study, eight participants were on disability resulting from their health and treatments. Of those
still working, all describe challenges and absences related to their condition.
The loss of work also contributes to the social impact of cancer in these individuals' lives.
As one subject noted:
Actually a lot of my coworkers have been some of my best friends. You go to the job every
day and you see the same people (Subject 13).
Beyond this, participants spoke frequently of the ways in which their social life was
restricted because of their compromised immune systems. This was particularly challenging for
participants with children attending school and for grandparents wanting to watch and spend
time with their grandchildren while they still had time.
Additionally, participants described losses of parts of their identity and support
structures, such as continuing to pursue their passions and hobbies or attend social gatherings or
religious functions. The physical constraints and experiences of the disease and the treatments
further impact even daily basic activities of participants such as driving, cleaning, cooking,
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dressing and even getting out of bed in the morning. Participants describe difficulties fulfilling
obligations to their family and having to ‘push through’ and ‘pay for it’ in pain to get things
done. All participants described impacts on their daily routines, but the worst were related to
limitations due to pain. As one subject described:
When I get the pain, the tiredness and nausea, when it hits, you can’t do anything. You’re
in bed, you’re moaning, it just hurts so much (Subject 6).

Perceptions and experiences of pain management strategies
In attempting to manage their pain and symptoms, participants describe the varying ways
that they are guided by health providers, self-guided research, and family and friends. The
majority of the participants explained that their doctors and pain management teams typically
recommended a prescription for an opioid as the first line option for pain management. Their
health care providers provided recommendations for the use of medical marijuana for pain and
symptom management to less than half the participants. Some of the subjects hypothesized that
this was because their health provider was not certified to register them for a medical marijuana
card and/or lacked knowledge about the uses of medical marijuana. Of those that did receive
recommendations for medical marijuana from their providers, the majority were in cases in
which the opioids had not provided adequate pain relief or as a recommendation for improving
sleep, appetite, or treating anxiety.
Many of the subjects reported being the ones to initiate discussions with their health
providers regarding the potential benefits of medical marijuana. The responses of the health
providers ranged from supportive to dismissive of the suggestion. One participant describes their
experience:
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We brought it up to our oncologist and they didn’t even advise us where to go. They just
said well, you know, we don’t really know a whole lot about it, studies have been done. We
would suggest some Percocet, some Vicodin. (Subject 1).
The majority of the research participants described some level of self-driven research
contributing to their decision to incorporate medical marijuana into their care routine. As one
subject stated:
I have to do it myself. There’s research involved. That was my struggle. But if you get the
right team together, that’s the best way to manage the pain. And I think I did that. And I’m super
happy I have a medical marijuana card. It’s been a lifesaver so far (Subject 4).

Five of the participants described advice from friends and family as being the major
deciding factors for convincing them to incorporate medical marijuana into their management
regime. In recounting the advice from friends and family, participants often emphasize how
knowledgeable these people were about the current research on both medical marijuana and
cancer.
Study participants also had varying experiences and perceptions of the process they had
to go through for their pain management strategies. Most agreed that they had straightforward
access to their opioid prescriptions through their pain management doctor, although a few noted
that the increased regulations imposed in recent years had made the process more challenging.
As one participant stated:
I know before this opioid crisis started, my doctor give out my pain medication to me. We
had no problems. We managed the pains right. Just like I'm doing now with the pain specialist.
Now I have to see two different people (Subject 20).
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Participants also noted that they have to let their doctor know monthly when they are out
of their opioids, as they are not allowed to have refills and it must be called in each month. For
medical marijuana, participants noted that it was possible to get a few months’ supply at one
time. However, the process of getting and maintaining a medical marijuana card was variable.
Some participants had to pay a three hundred dollar fee for their medical marijuana card while
others said they got theirs free. This discrepancy did not correlate with income or insurance type
but may have had to do with the policies in place at the time that they applied for their card.
Some subjects reported that their doctor pushed the application through and they were registered
quite quickly, while others described stumbling through the process with minimal guidance and
support and waiting weeks to get their card. One participant describes his navigation of the
process:
That was hard, as far as how to get everything, because it's a process. First you got to get
the appointment with the specialist and then, he's got to do his paperwork. If you pay a copay.
Then you got to go online and you got to do this and then they send you a temporary license and
then you got to make an appointment with the dispensary and all that stuff. So not knowing all
that process was kind of tough. I mean, I have done it, it's fine, but a lot of little steps. Which I
know it could be easier. Probably just easier to get your opioid medications (Subject 13).

Many participants describe the process as a lot to navigate when you are already ill and
managing all the other aspects of your cancer and treatments.
Access to medical marijuana also emerged as a salient theme in participants’ experiences
of cancer pain management, particularly in terms of distance to dispensaries, access to their pain
management regime while in hospital, and access to illicit forms of marijuana. While a few
participants noted that they had some challenges with physically accessing their opioid pain
medication (for example if they were going out of state), most described their access to opioids
as a fairly simple matter of filling a prescription at the local pharmacy, or sending someone to
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pick it up on their behalf. Access to medical marijuana was much more variable between
subjects. Dispensaries were local and convenient for only three of the research participants. The
remaining subjects reported the nearest dispensary between forty-five minutes to two hours from
them. Further, participants had varying perceptions and experiences on getting a caregiver card
to allow someone to pick the medical marijuana up on their behalf if they could not make the trip
themselves.
Lived experiences of access to pain management while in hospital also varied. Two
participants who had used medical marijuana to replace opioids in their pain management
strategy described hospital experiences where they did not have access to any form of pain
medication as follows:
If they could prescribe medical marijuana, I would have been fine. I told them it's not that
I want a narcotic, it's that it's acute pain (Subject 18).

One participant ended up in hospital for five weeks without access to medical marijuana,
which was the only thing he had found to be effective for his neuropathy. From his hospital bed,
he petitioned the hospital and reported:
It took me over a month to get them to change their rules to get the medical marijuana
allowed to be taken there. I had to change the policies of the hospital which took me about five
weeks I think, to change their policies and it was a tough fight (Subject 9).

Due to the additional processes for gaining access to medical marijuana, a number of
participants described accessing illicit forms of marijuana first to determine if it provided them
with any benefits before going to the effort of obtaining it legally. Two study subjects even
stated that their doctor recommended they go this route. Some participants were able to access
regulated forms of marijuana while visiting other states or obtain it from someone with a medical
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marijuana card. Others obtained unregulated forms through friends or family members or by
‘knowing a guy’. However, a few participants described experiences that highlight the potential
negative impacts of lacking guidance and dosage recommendations during an initial trial
experience.
All participants with a wide range of experiences discussed the effectiveness of opioids
and medical marijuana for treating pain and other symptoms that affect an individual’s quality of
life. Opioids were spoken of only in terms of managing pain and inflammation, whereas medical
marijuana was spoken of in terms of management of pain, neuropathy, mental health, sleep,
appetite, and muscle relaxation. As one patient expressed:
The marijuana pill, it takes care of more than one issue. It gets me out of the depression,
it helps me to want to get up and do things and actually get up and do things, it helps with the
anxiety and the depression and the pain (Subject 18).
Participants also describe the ways in which the benefits provided by medical marijuana
for other symptoms also helps them manage their pain. For example, eating and sleeping
regularly were linked to improved immunity to withstand the cancer and treatments.
Inflammation and muscle tension can contribute to experiences of pain, so by reducing the
inflammation and muscle tension in the body, participants experienced longer pain relief
benefits. Besides physically reducing the tension, some participants also described that the
impact medical marijuana had on reducing their anxiety helped them face and manage their pain
better, commenting:
It takes away my anxiety and it lets me be me for a little bit. If I don't vape, all I think
about is pain, I can't handle this, I can't take this (Subject 15).
In terms of the effectiveness of opioids and medical marijuana for directly managing the
pain, respondents reported very individualized experiences. Some described the opioids as doing
nothing for the pain other than making them comatose, others describe their pain as
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unmanageable without opioids. Some participants that did find pain relief from their opioids
mentioned that the relief only lasted a short amount of time and wore off before their next
scheduled dose. Participants had similar varying experiences of medical marijuana’s impact on
their pain. One participant describes his experience:
The problem I have with marijuana is the marijuana doesn't actually go directly to the
pain. It goes to your brain (Subject 20).
Others described their experience using medical marijuana as ‘life changing’ or ‘night
and day’ for managing their pain. When discussing the effectiveness of medical marijuana, the
majority of subjects also had experiences of needing to adjust their dosage and ratio of THC to
CBD to find what would address their pain effectively. Participants also discussed variation in
the effectiveness based on product type. Many subjects described a mixed regime of opioids and
medical marijuana for effectively managing their pain.
Subjects also discussed variable experiences with side effects. Side effects associated
with opioids included nausea, depression (“oxy blues”), lethargy, irritability, feeling high or a
general ‘terrible’ or ‘yucky’ feeling. Experiences of the side effects differed dramatically
between participants with some reporting no side effects and others describing themselves as ‘no
longer functionally human’, ‘gone’, or ‘not themselves’. Managing the sometimes-manifold side
effects from the opioids led many participants to additional medications such as sleeping pills,
laxatives, anxiety medication, and nausea medication. Many of these additional medications also
proved to have side effects. With the complexity and evolving nature of patients' experiences and
regimes for treating and managing their cancer and associated symptoms, the lived experience
can become difficult to parse out as mentioned:
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I seem to have so many side effects, at different times, that I don't know. But then again,
I'm taking so many different meds. I don't know what's from what you know, I have no idea what
the side effects (Subject 13).

Side effects associated with medical marijuana included increased appetite, feeling high,
unfocused, paranoia, and lightheadedness. While there was variation in the side effects
experienced by study subjects, most reported the side effects to be very mild. Increased appetite,
the most commonly described side effect, was reported by all but one participant who
experienced it as a benefit for their condition. As one subject expressed:
I don’t have any negative side effects with it, other than the munchies. And as far as I’m
concerned that’s not a negative, not with what I’m dealing with. I’m somehow maintaining my
weight when I shouldn’t be (Subject 4).
However, one participant, who had been trying to lose weight, listed this side effect as a
drawback. Experiences of feeling high also varied, the majority reported that they did not feel
high from their medical marijuana, while a few described the higher THC dosage products
hitting them ‘like a ton of bricks’. In those cases, participants described working with the
pharmacist to find a balance that did not make them feel high. One participant experienced
severe lightheadedness that she attributed to taking her oil while anesthesia from her surgery was
still in her system, and another experienced a mild case of paranoia on one product that she tried.
Another relevant theme that emerged in discussing pain management was the experience
and perception of stigmas and fears associated with both opioids and medical cannabis. A few of
the study subjects described experiences of stigmatization from health providers regarding their
opioid usage. These participants expressed frustration and despair at their pain being treated
dismissively and at the perception that their health provider thought they were lying. One of the
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participants in this study describes how confronting it is to be in intense chronic pain and have
multiple health providers dismiss your attempts to find effective pain relief either through
opioids or medical marijuana. As she stated,
They thought that I just wanted opioids because I had addiction and that I was faking it
and that I just wanted to get high on medical marijuana. That's an awful thing to be told (Subject
15).

Beyond medical providers being hesitant about the opioid addiction, the majority of
participants themselves expressed a fear of becoming too dependent. You cannot turn the TV on
without realizing that billions of people are hooked on oxycodone, as stated by one subject:
That's my biggest fear. I don't want to go down that road. That's why I thought I would
find a substitute (Subject 11).
Four of the study participants refused to take opioids, opting for over the counter options
or medical marijuana to manage their pain. Many participants had personal experiences with
friends or family with addictions that contributed to their fear of becoming addicted themselves.
As one subject noted:
My big thing with opiates is I’ve seen what it did to my brothers. They’re like full-blown
junkies and it’s sad (Subject 4).

Beyond addiction, some participants also brought up reservations about the safety profile
of opioids and the effects of adding those chemicals on top of all the other shocks to the system.
Many participants struggle with balancing their pain experiences with fear of what opioids are
doing in their bodies:
You read stuff about opioids and how they, you know, destroy your body and I get my
kidneys and my liver checked. I get my blood work done every so often to see how everything's
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handling because I'm 63. I've been on it since 50. So it's up to god what's going to happen to me.
You know, I don't know (Subject 15).
While stigma-surrounding opioids is increasing, most participants as decreasing
described stigma in relation to medical marijuana. However, some study subjects still
encountered stigma and fear surrounding their use of medical marijuana. One participant
described hiding his self-medication with medical marijuana from his health providers for fear of
being stigmatized as a junkie and denied treatment. Another relayed his fears surrounding drug
testing at his job, as it is still a federally illegal substance. Some perceptions of stigma are more
subtle and contradictory. One man who prided himself on never participating in drug and alcohol
culture described the contradictory response of his family when transitioning from opioids that
made him ‘aggressive’ to a medical marijuana product:
The only thing I can say is with the medical marijuana my family all wanted me to do it
and then once I did it, my family all uses it against me, because I'm now a ‘pothead’ or
something. Everything changed, like the grandkids don't come over anymore. It just kind of hurt
my feelings (Subject 9).
While all participants proclaimed themselves to have always been pro-legalization of
medical marijuana and many reported even being pro-recreational legalization as well, this was
not always apparent in their actions. Many participants described initial resistance to getting their
medical marijuana card exemplified in the comment:
I wish I had listened to my husband before that. Because I kind of resisted for a while, I
said no I don’t want it. It really made a big difference (Subject 17).
Others expressed fear of taking as much as was recommended. The most commonly
expressed fears around medical marijuana were about uncertainty of how it would affect them,
using it when they were alone, or using it during the day when they needed to work, drive, or
care for children. Even participants that said they did not feel side effects from the medical

93

marijuana product expressed these concerns. When asked further about these concerns, most said
that they had not yet tested it and wanted to be cautious.

Perceived benefits of medical marijuana
Themes surrounding subjects perceived benefits of adding medical marijuana into their
management routine included the effectiveness in treating symptoms, the non-addictive nature
and strong safety profile, the ability to take as needed, the immediate and extended relief, and the
reduced dependency on opioids and other prescriptions. As described previously, some
participants described medical marijuana as effectively treating pain or other symptoms that had
previously been unmanageable with other treatment options. Many participants extolled the
benefits by describing activities that they had not been able to do for years and now were able to.
Effectively addressing pain, insomnia, appetite, depression, and anxiety reduced the negative
impacts on social lives and daily activities and greatly improved quality of life. As one
participant stated:
I would go into any oncologist’s office and say ‘get your medical marijuana card, you’ll
be a human again’ (Subject 5).

Participants also discussed the benefits of medical marijuana in terms of the safety profile
of the drug and the fact that it is non-addictive. One of the study subjects who had admitted to
smoking marijuana for the majority of his adult life even before getting his medical marijuana
card, had actually chosen to quit taking his medical marijuana ‘cold turkey’ after he no longer
needed it for his treatments. When asked about any withdrawal symptoms he stated that he had
not experienced a single symptom of withdrawal and felt great. He contrasted that with the
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withdrawal symptoms he had experienced years prior when he had been on opioids for a short
time following a knee surgery. Participants described reduced anxiety around addiction when
using medical marijuana as well.
The safety profile also allows prescriptions for medical marijuana to be much more
frequent and flexible than structured opioid regimes. Many study subjects discussed the benefit
of this for providing them with more control to effectively manage their symptoms.
The pain pills were helping but it wasn’t really doing anything on a long term, just about
six hours would be up and I knew it was about to be up because the pain would start immediately
right back in (Subject 10).

In addition, as noted above, participants often described a lot of variability in their pain
experiences, with good and bad days. In managing his unpredictable pain, a study subject
explains:
It's very random, it’s not like I can take the same thing every day and it's going to work,
you know? (Subject 13).

The immediate effects of medical marijuana on the system in the comment also bolstered
the additional sense of control:
I could take as much as I needed, maybe a puff or so whenever I felt it was coming and
before it got really bad. It helped me have control over what I took and how often. It was really
quick also. The effect was not the 20 minutes you have to wait with the pills, it was within a
minute or so. That also relieved a lot of anxiety because I felt like I am in control and it’s not
making me drowsy (Subject 17).
A few participants also noted their experience with more extended benefits from taking
medical marijuana. Many participants noted being woken up by pain or feeling terrible in the
morning after their nighttime dose of opioids wore off. However, a few study subjects noted that
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since they started taking medical marijuana at night, their morning symptoms seem to be relieved
as well.
Another perceived benefit of adding medical marijuana into the subject’s management
routine was the reduced dependency on opioids and other medications. Medical marijuana was
noted as having the potential to reduce opioid dependency for both addicts and for those
developing a tolerance to their pain management regime. For patients that were maxed out on
their opioid dosage and still unable to achieve pain control, the addition of medical marijuana
into their regime provides a much-needed additional source of relief. For patients concerned with
developing a tolerance or addiction, this option for reduced dependency helps mitigate that
anxiety. Further, many participants noted that reduced dependency on opioids would also reduce
their opioid associated side effects and improve their quality of life. One participant described in
detail the months of suffering through chemotherapy and the opioid induced lethargy and
depression before switching to medical marijuana, concluding:
We lived three almost four months of hell. I wish we would have got the [medical
marijuana] sooner and didn’t have to do the fentanyl patches and the oxycodone, because that
stuff actually took quality time away (Subject 5).
Additionally, participants noted reductions in their reliance on other medications to treat
the side effects, including anxiety medications, depression medications, nausea medications, and
laxatives. A few participants also reported reduced or ended regimes of self-medication as
follows:
I was actually drinking very heavily. I got to the point where I could sleep if I was
hammered. And obviously, I don’t drink anymore. I’m sleeping fine with it (Subject 4).
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Enablers of improved pain management
Enablers of improved pain management that emerged out of this study include the
support of family and friends, the support of health providers, the support of employers, and
exposure and awareness about medical marijuana. Family and friends played an integral role in
almost every subject’s story. For some, they contributed to awareness and knowledge about pain
management options as discussed above. For others, they advocated on their behalf to the health
providers or provided backing for their decisions in the comment:
There's not a lot of information about this. You have to ask and re-ask. It's great to have
people in your corner. When you have someone like that, you have another set of ears in there
with you (Subject 14).
Family and friends also played roles in terms of financial and logistical support,
providing rides, helping with daily activities and chores, and picking up prescriptions. In terms
of medical marijuana, family support of the use seems to be pervasive across almost all stories
and has been an enabler for incorporating it into the individual’s pain management routine.
Notably, in the one case where the participant described that his family had stopped bringing his
grandkids around, it had been the same family members that had convinced him to switch to
medical marijuana and continued to verbally support that decision.
Another major enabler for improved management emerging from subject reported
experiences was a trusted and supportive medical team or health provider. Participants that had
good working relationships with their medical team and described their health providers as
supportive of their decisions and preferences were frequently the ones that had an easier time
navigating the process of obtaining their medical marijuana card, were processed more quickly,
and described their experiences in a more positive way. Even in cases where only one health
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provider on an individual’s medical team was supportive, it was often enough to expedite the
process.
Another enabler for improved management strategies that emerged was exposure and
awareness of the uses of medical marijuana. Having exposure to people who have had successful
experiences with medical marijuana raised subjects’ awareness and knowledge about the
potential for it to be a beneficial addition to their own management strategy.
Knowing people that use medical marijuana or having prior experience themselves also
contributed to an understanding of what the personal experience and benefits might be. One
participant explained her experience with medical marijuana as follows:
My niece has a brain problem. And they put her on it. And I tried it and I liked it. You
know, I said, it does work (Subject 10).
Exposure to others using medical marijuana was also useful for overcoming fear and
stigma surrounding medical marijuana as mentioned in a subject’s statement:
I never had anything against it because I’ve seen what it’s done for my brother. I’ve seen
people who have cancer who have used it through hospice care (Subject 7).
However, it is worth noting that prior experience with recreational marijuana may act as
an enabler or a barrier depending on the person. Some subjects mentioned prior experience with
recreational marijuana and in three of these subjects, this prior experience made them more
reticent to use medical marijuana. The reasoning was that they did not want to become the
person they used to be. However, these participants reported that these fears did not materialize
when they started medical marijuana.
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Barriers to pain management
When asked about the greatest challenges to the incorporation of medical marijuana into
management regimes participants almost unanimously identified financial impacts and lack of
integrated services. Nearly all participants regardless of whether or not they found the cost
prohibitive mentioned the cost of medical marijuana. As a federally controlled substance,
medical marijuana is not covered by health insurance, so incorporating it into a pain management
strategy necessarily causes a financial impact:
The price is very expensive. It's not cheap and without insurance covering it, it gets very
expensive. The opioid medication is covered under my insurance (Subject 20).
Some participants described medical marijuana as very expensive but ‘worth it’. For
others, they spoke about it as a commitment, a choice that you make and budget and sacrifice for.
Others spoke of the cost as prohibitive; shaping their pain management strategy by what they
could afford as opposed to what most effectively managed their chronic pain and provided them
with quality of life. One woman describes an experience that echo many other subjects’
experiences:
I have the green, yellow and red. The red one actually helped me the most, it just came
down to the cost of it. I just couldn’t afford to go to that one, so I went to the yellow one, because
it was cheaper (Subject 7).
In addition to paying for the medical marijuana products themselves, some participants
also had costs associated with obtaining the medical marijuana card:
I can still not wrap my head around why it cost us three hundred bucks when we’re
having all this hardship, all the problems. It cost me three hundred bucks that I had to scrimp
and scrounge for. I’m not kidding, I literally counted change for that. So, it cost us three hundred
bucks to get this card, but there is no co-pay at the pharmacy for this oxycontin or fentanyl. How
does that even make sense? (Subject 5).
A few participants also mentioned indirect costs associated with having to take time off
work and pay gas to drive an hour and a half to three hours round trip to the nearest dispensary.
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Especially at a time when subjects are already experiencing income loss, medical expenses, and
other indirect cost in association with their condition, the monthly and indirect costs of medical
marijuana can prove to be a substantial barrier that negatively affects peoples’ quality of life. As
one study respondent expressed:
I just wish I could afford it more. That’s why I agreed to do this, because it’s a terrible
thing to have to make people feel there’s no hope for them. They know it’ll help them, they just
can’t afford it (Subject 7).
A few participants also noted that the cost barrier might drive patients to find cheaper
options from illicit sources. One participant noted the safety issues already emerging around
vape pens being sold on the street where the marijuana has been cut with other ingredients.
The other barrier for improved management strategies in general, and the incorporation
of medical marijuana in particular, that emerged in nearly every research participant's story was
the lack of integrated services. In describing their health management and their medical team,
study subjects frequently mentioned as many as nine different health providers and specialists
they were working with. Prescriptions for opioid medications, steroid shots, and medical
marijuana may all be managed by different doctors with the patient themselves either managing
the master list of prescriptions or bringing the list with them to share with and update each of
their various health providers.
Further, subjects described the wide variation in knowledge or awareness about medical
marijuana, its uses and potential benefits, and the process for obtaining it among health
providers. This resulted in knowledge gaps and conflicting or no guidance provided to the
subjects and contributed to stress and anxiety in trying to manage a serious illness within a
fractured system. As one participant expressed:
I guess I was just scared. They need to have a better dialogue for people or something to
make it more open. If you're not looking for it, there's nothing really that comes after you to get
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it. There's no information out there that's readily available for you to get medical marijuana
(Subject 9).
Additionally, inconsistencies within the larger health system create barriers for patients
who have incorporated medical marijuana into their management routine. Many of these
participants end up in hospital for extended periods for various reasons as they are dealing with
serious, and often life threatening, conditions. However, depending on the policies of the
hospital, patients may be deprived of their medications. One participant highlighted the
inconsistencies in policy that left him with unmanaged pain while hospitalized explaining:
Here's the thing, they prescribe medical marijuana for patients there, but they would not
give medical marijuana on their property to patients (Subject 9).
All the participants in this study agreed that when faced with a debilitating condition,
services should be integrated to improve access to options for management strategies that can
have dramatic impacts on a person's quality of life. One participant stated:
There is a need for more choices, as in the medical marijuana through the hospital,
through oncology, through the pharmacies, to where you don’t have to go to a specialized place
for this stuff (Subject 5).

Discussion
Cannabis-based medication was administered to a cohort of 20 subjects with cancerrelated neuropathic pain at an upstate NY dispensary. Their lived experiences with cancer and
cancer treatments, their pain management strategies including opioid and cannabis basedmedicines, and factors that enabled or presented barriers to their effective pain management were
ascertained via in-depth, semi-structured phone interviews. The lived experiences of participants
with cancer, treatments, and the resultant symptoms and impacts on their quality of life varied
dramatically, both between subjects and within individual experiences. This included their
respective management strategies addressing the breadth of cancer-related pain. These
101

observations suggest that cancer-related pain may relate to the type, location, treatment, and
stage of disease, which is expected to vary among a cohort such as this unselected for any of the
aforementioned aspects.
Individual experiences in cancer-related pain and the management of it affected subjects
differently notwithstanding the similarity in baseline analgesic therapy. Altogether, 80% of
subjects were taking opioid pharmacotherapy to treat severe neuropathic pain before adding
CBMs in oral capsule, sublingual tincture, inhaled vaporized forms, or a combination thereof.
Some of these subjects were failing to achieve effective management with opioids alone, other
subjects were experiencing effective pain relief but having to manage negative side effects from
the opioids that they were hoping to mitigate, and still others achieved no noticeable relief from
the opioids.
Those subjects who had refused opioid medicines and opted to use CBMs as their first
line strategy for management of pain and symptoms cited prior experiences with opioids that
made them unacceptable or undesirable. Cannabis-based medication provided a socially
accepted, safe and well-tolerated adjunct or alternative to opioids in this cohort. The foremost
challenge of the cohort was in formulating their own strategy of pain management, combining
available multimodality aspects. The addition of CBMs to participants management strategies
not only provided an option that was more effective for some subjects and some types of pain, it
also improved the flexibility of subjects' pain management strategies providing individuals with
more control over addressing their own fluctuating pain experiences.
Further, CBM mitigated a variety of other symptoms common among cancer patients that
opioid medications do not address and often can exacerbate. These include insomnia, nausea,
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weight loss, anxiety, and depression. In this way, the inclusion of CBMs into patient pain
management strategies had knock on effects and was able to reduce not just patient dependency
on opioid medications, but reduce the number of medications they were taking to treat other
symptoms. These various lived experiences of cancer and its management highlight the need for
improved options and adaptability for achieving optimal pain and symptom control. Lack of
integration proved to be a major barrier for subjects creating and maintaining an effective pain
management strategy. CBM should be integrated into pain management regimes to ensure that
patients are consistently provided with knowledge about the range of options available to create
an individualized strategy that effectively meets their needs, to ensure that they have consistent
access to the various medications in their strategy, and to ensure it is affordable for them to
maintain.
The historical background of CBM provides a useful guidepost to its present role in
cancer analgesia especially as an adjunct to opioid pharmacotherapy. Nearly a half-century ago
investigators (3, 4) established the tolerance, efficacy and equivalency of THC compared to
opioids using single-dose analgesic methods to study the relative efficacy of a 5, 10, 15 and 20
mg dose of oral THC over a 6-hour period and its benefit compared to placebo in cancer pain.
There was significantly analgesia compared to placebo especially at 15 mg, which was well
tolerated despite sedative effects and mild mental clouding. A 10 mg dose of THC was
comparable in its analgesic effects to 60 mg of codeine with only mild sedation. Such patients
incidentally had improved mood, sense of well-being, and reduced anxiety.
Van den Beuken-Van Everdingen and colleagues (5) later performed a meta-analysis of
the prevalence of cancer pain in published literature from up to 2014, noting that among 122
studies the prevalence of pain was 39.3% after curative treatment; 55.0% during anticancer
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treatment; and 66.4% in advanced, metastatic, or terminal disease. Moderate to severe pain (in a
numerical rating scale score ≥5) was reported by 38.0% of all patients. The authors concluded
that despite increased attention on assessment and management, pain was a prevalent symptom
in cancer. The authors concluded that in the decade ahead, it was incumbent upon physicians to
develop and implement effective interventions in cancer pain. Hence, the importance of
integrating medical cannabis into the available modalities of pain management at all stages of
cancer care.
Johnson and colleagues (6) reported their experience in the treatment of intractable
cancer pain employing non-pharmaceutical preparations of whole-plant extract cannabis in a
study of 177 patients who experienced inadequate analgesia despite chronic opioid dosing.
Patients were randomized to a tetrahydrocannabinol: cannabidiol (THC: CBD) extract (n = 60),
THC extract (n = 58), or placebo (n = 59). The primary analysis of change from baseline in mean
pain. A numerical rating scale score showed statistically significance in favor of THC: CBD
compared with placebo (improvement of -1.37 vs. -0.69), whereas the THC group showed no
significant change (-1.01 vs. -0.69). Twice as many patients taking THC: CBD showed a
reduction of more than 30% from baseline pain NRS score when compared with placebo (23
[43%] vs. 12 [21%]). Hence, THC: CBD extract was highly efficacious for relief of pain in
patients with advanced cancer pain not fully relieved by strong opioids.
This was followed by the first randomized placebo-controlled graded-dose trial (7) of
patients with advanced cancer and opioid-refractory pain randomized to low dose (1-4
sprays/day), medium dose (6-10 sprays/day), or high dose (11-16 sprays/day) nabiximols
(Nabiximols is the U.S. Adopted Name [USAN] for Sativex® [GW Pharma Ltd, Wiltshire, U.K
) or placebo. Among 263 subjects who completed questionnaires of their QoL and mood and an
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assessment of average daily pain, worst pain and sleep disruption during 5 weeks of treatment
there was a response rate of 30% responder rate in a primary analysis that did not differ between
nabiximols versus placebo (overall P = .59). However, a secondary continuous responder
analysis of average daily pain from baseline to end of study demonstrated that the proportion of
patients reporting analgesia was greater for nabiximols than placebo overall (P = .035), and
specifically in the low-dose (P = .008) and medium-dose (P = .039) groups. In the low-dose
group, results were similar for mean average pain (P = .006), mean worst pain (P = .011), and
mean sleep disruption (P = .003). Adverse events were dose-related and only the high-dose group
compared unfavorably with placebo. This study supported the efficacy and safety of nabiximols
at the two lower-dose levels and provides important dose information for future trials.
Although this is the first study conducted in an outpatient community dispensary via in
depth interviews and supported by pharmaceutical monitoring of dosages to study cancer
analgesia, a recent analysis of medical cannabis users in a comparable setting may provide useful
insights. Yau and colleagues (8) recruited 100 medical cannabis users from a community
dispensary in Vancouver Canada who completed a structured clinical interview including the
Mini-International Neuropsychiatric Interview, Perceived Stress Scale-10, Patient-Reported
Outcomes Measurement Information System (PROMIS) Fatigue Scale, PROMIS Sleep
Disturbance Scale, Beck Depression Inventory, the Patient Health Questionnaire-15 and the
Brief Pain Inventory. The investigators noted that among this population, 50% met criteria for a
prior but not current major depressive disorder (MDD), 43% had anxiety disorders, and nonalcohol substance use dependence and substance use was diagnosed in 42% including drug
dependence within the past year. When subjects were asked to choose one specific condition as
their primary reason for using medical cannabis, anxiety (43%) was the most common condition
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followed by insomnia/sleep issues (18%) and depression (16%). Of note, the small cohort was
not selected using standard epidemiological techniques, and so extrapolation to the general
population as a whole may not be valid. However, if the subjects chosen at random are
representative of at least the types of individuals who use cannabis dispensaries this has
implications for the present study, there may be implications for the present study.
One other study examined medical cannabis from a dispensary member’s perspective in
New England (9) in a sample consisting of patients with chronic pain from a variety of
overlapping sources including back-pain, arthritis, neuropathic pain, post-surgical pain,
abdominal pain, and headaches but not cancer who completed an educational intake session
lasting 45 minutes and a 77-item online survey with forced-choice demographics and medical
history items and open-ended questions. In response to "How effective is medical cannabis in
treating your symptoms or conditions?" with options of 0% "no relief" to 100% "complete
relief," the average was 74.6% ± 0.6. The average amount spent on MC each year was $3064.47
± 117.60, median = $2320.23, range = $52.14 to $52,140.00. In this study, open-ended responses
were coded into themes and subthemes. Analysis of answers to "What is it that you like most
about medical cannabis (MC)?" (N = 2592 responses) identified 10 themes, including health
benefits (36.0% of responses, for example, "Changes perception and experience of my chronic
pain."), the product (14.2%, for example, "Knowing exactly what strain you are getting"), nonhealth benefits (14.1%), general considerations (10.3%), and medications (7.1%). Responses (N
= 1678) to "What is it that you like least about MC?" identified 12 themes, including money
(28.4%, for example, "The cost is expensive for someone on a fixed income"), effects (21.7%,
for example, "The effects on my lungs"), the view of others (11.4%), access (8.2%), and method
of administration (7.1%). The largest positive theme identified, which related to health benefits
106

illustrated how respondents described in great depth how medical cannabis improved their
treatment of chronic-pain and enhanced their quality of life. The primary negative theme
identified however was cost, which varied depending on the formulation and the preferred route
of administration. Medical cannabis, unlike other treatments for pain such as opioid
pharmacotherapy, is not covered by insurance; so this fiscal finding is unsurprising. These
findings provide a patient-centered view on the advantages (for example, efficacy in pain
treatment, reduced use of other medications) and disadvantages (for example, economic and
stigma) of medical cannabis.
There are several limitations to this study. First, subjects were prescribed a CBM in the
ratio of THC: CBD of 1:1 and, depending upon analgesic and side effects, advanced to higher
proportions of THC: CBD. Pharmacists were generally ignorant of the opioid-doses prescribed
by their pain management physicians so there was little opportunity to overtly diminish their
tolerance of opioids or balance the dose of CBM with opioids to improve analgesia. This was
generally left to the patient with the advice of their pain management physicians often based
more on individual patient preferences than the collective wisdom of a single guiding medical
philosophy.
Second, the cohort was not screened for opioid abuse, substance usage, or psychiatric
disease that might affect their tolerance and dependence upon cannabis and opioids. Clients who
visit marijuana dispensaries to obtain medical cannabis for pain appear to be at heightened risk
for a psychiatric illness with a greater likelihood of abusing cannabis and opioids when they selfmedicate (10). Their choice of the CBM product and route of administration may be different
that recommended by the pharmacist as for example vaporizing versus capsules in those who
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prefer to simulate smoking weed. However, there is no evidence that a given CBM alters
efficacy or the corresponding dose of opioids.
Third, subjects also took CBM for reasons unrelated to neuropathic cancer pain to
manage cancerous symptoms of cancer-related nausea, vomiting, anorexia, weight loss and
cachexia due to cancer, chemotherapy and radiation therapy to improve QoL (11-14).
Fourth, the number of subjects was small and the types of cancers varied making it
difficult to generalize the response to CBM and other analgesics to a single type of cancer. Apart
from the diversity of cancers surveyed, study subjects were in different stages of their cancer and
in different phases of their treatment and recovery, all of which could affect the level of pain and
the root cause such as chemotherapy, surgical, or metastatic spread.
Fifth, inhaled delivery of cannabis has historically been the preferred method for fast
action, but the rise in respiratory syndromes associated with vaping (15) has contributed to a
decline in this route of administration. Moreover, some subjects may feel the stigma of
vaporization and switch to, or combine it with other preparations even when it has been effective
and well tolerated. Ultimately, the effectiveness of the given regimen of CBM may have been
adversely affected.
Sixth, the decision to taper opioids and continue CBM was implicit in their participation
but it was not a criterion for their continued inclusion.
Seventh, Amazon gift cards were given out to subjects at entrance and exit of the study,
which in those with limited financial means may have incentivized them to participate beyond
their inherent desire to take CBM or taper off opioids.
Eight, the emergence of COVID-19 pandemic led the Honorable Andrew Cuomo,
Governor of NYS to decree a state of emergency on February 24, 2020 for all New Yorkers.
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While the Vireo Health dispensary was able to continue operating with social distancing
precautions, those with severe comorbid diseases were encouraged to shelter-in-place and
communicate remotely. With the increased burden of COVID-19 on its business operation, study
protocols were cancelled. This precluded a comparative prospective analysis of monthly
estimated drug costs, efficacy of CBM in allowing a tapering of opioid doses, and a formal CEA
of the two drug classes.
Ninth, the level of pain at entry by Vireo Health via PEG and VAS, which was found to
be severe, was derived from a minority (40%) of subjects. It is unclear why other subjects were
not scored but if this was an elective process by the dispensary, it suggests at least a bias of
reporting by those most severely affected and possibly not representative of the cohort. The
agreement between PEG and VAS is reported to be excellent (p=0.90, 95% confidence intervals
[CI] =0.86-0.93). However, both have limitations. Specifically, investigators (16). In contrast,
investigators (17) find that VAS scores may be skewed by the introduction of a crying face in
individuals that come from cultures that find crying to be less acceptable or honorable thereby
under-reporting pain levels. Fear and anxiety may bias pain reporting and interfere with attempts
to measure intensity. Moreover, the reliability of PEG and VAS reporting may be influenced by
the performance of practice sessions beforehand that the dispensary did not conduct.
Lastly, other specific data of ethnicity and educational background, such data if collected,
could be clues to evaluating or contextualized subjects’ responses in relating to socioeconomic
status.
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Conclusion
Overall, the present study identified many perceptions and experiences about the
efficacy, and barriers, to incorporating CBM into pain management strategies for improving pain
and symptom control and quality of life among patients with cancer-related neuropathic pain.
Independent of individual providers or their institutions, such views about medical cannabis as
adjunctive or alternative therapy to opioid-based pharmacotherapy may enhance its role in the
multimodal approach to chronic pain. Although this study is limited in some ways, it does
provide a window into the chronic pain patient’s favorable and unfavorable experiences with
CBM. It is increasingly apparent that the patient’s perspective is important in the successful
management of chronic pain. An important next step following up on the results of this research
is to work collaboratively with Vireo Health to extend the findings, and establish algorithms and
guidance for patients seeking to wean off opioid drugs with adjunctive CBM.
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Table 1
Characteristics of Study Participants (N=20)
N. (%)
Men

8 (40)

Woman

12 (60)

Mean age (years)

59.5

Tumor type
Lymphoproliferative

7 (38)

Breast

3 (16)

Lung

2 (11)

Ovary

1 (6)

Skin

1 (6)

Prostate

1 (6)

Gallbladder

1 (6)

NA

2 (11)

Cannabis Product at Entry
Oral only

7 (35)

Sublingual only

2 (10)

Inhaled only

4 (20)

Combination

7 (35)

Taking Opioids at Entry

16 (80)

Mean Pain Score (n=8)
PEG

5.7/10

VSEG

4.25/5

Employment
Disabled

8 (44)

Retired

6 (33)

Full-time

3 (17)
113

Part-time

1 (6)

NA
Abbreviations: PEG, average pain intensity, interference with enjoyment of life (E) and activities
(G); VAS, visual analog pain scale; NA, not available; N., number.
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Table 2
Emergent Themes and Subthemes
Themes

Sub-themes

Sources of pain and
discomfort

Cancer
Treatments
Medications

Impact on life

Social
Work
Daily
Mental health

Management routine

Health care visits
Medical team
Time management

Guidance

Medical team
Friends/family
Self-driven research
Pharmacist

Access

Prescribing doctor
Distance
In hospital
Illicit

Process

Opioids
Medical Marijuana

Effectiveness

Opioids
Medical Marijuana

Side effects

Opioids
Medical Marijuana
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Stigma/fear

Opioids
Medical Marijuana

Benefits

Non-addictive/safety profile
Frequency of use
Extended benefits
Reduced dependency on other medications

Enablers

Family/friend support
Employer support
Medical support
Prior experience/exposure

Barriers

Cost
Distance
Lack of integrated services
Product type
Dosing adjustments
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Chapter 5 - Conclusion
Introduction
Imagine you are sick with a chronic condition that either escapes understanding, such as
chronic pain, or worse, one for which there is no cure such as cancer. In the best scenario, you
hope for effective management by your physicians and their pharmaceutical options, yet the
choices are either limited or the ones you try may make you feel sicker. Consider also that the
US FDA has little say so in the approval of a medication, acting more as a marketing agent after
the pharmaceutical industry establishes its safety in clinical trials, and you will find that we have
not yet started an open dialogue about medical marijuana. This is unfortunate because there is an
extensive literature about the medical applications for cannabis. A recent book details the
history, speciation, genetic structure, pharmacology, pharmacokinetics, dosing, administration,
and safety of cannabinoid agents, and their role in maintaining homeostasis for the body during
chronic illness (1). This dissertation fills gaps in the present literature showing the reader, the
medical community, politicians, public health policy makers, and entrepreneurs and the
emerging marijuana industry, a way forward to harness its potential.

Summary and Relevance of Study Results
Chapter 2, Aim 1
Chapter 2 of this dissertation, based on Aim 1, was an analysis of the NYS Medical
Marijuana Program as seen through the lived experiences of a convenience sample of 12 key
stakeholders accessing and utilizing the medical marijuana program in New York State through
Vireo Health, Inc. The study participants, chosen for their willingness to participate in a research
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protocol without expectation of compensation, all underwent in-depth semi-structured
interviews. Among them, dispensary entrepreneurs, prescribing physicians, pharmacists, and
patients filling medical cannabis prescriptions in one or more dispensaries managed by Vireo
Health in New York. The choice of this study design and the SEF model to understand its public
policy implications was to capture the present interest in targeting personal, interpersonal,
organizational, community, and public policy concerns, relevant to disease prevention and health
promotion.
Overall, very positive thematic codes that emerged most frequently overall were
“Effective” and “Safe” as facilitators, and “Stigma” as a barrier. The code “Effective” was used
when participants were speaking about the effectiveness of medical marijuana as a medication
for various conditions and how this has been a facilitator for its legalization, acceptance, and use.
The code “Safe” was used to identify areas where participants spoke about the demonstrated
safety of marijuana as a medication, which has shown to be much safer than other legal drugs,
including being used to help patients come off opioids. It was also used to highlight areas where
participants noted that legalized versions or the drug is even safer because they are regulated.
The code “Stigma” was used to highlight areas when participants discussed misperceptions or
personal stigmas as a barrier to legalization, acceptance, and use. Many subjects extolled the
virtues, effectiveness, and safety of CBM, but admitted nonetheless that they would be
uncomfortable asking for or becoming a medical marijuana patient.
Notwithstanding, there was frank criticism of NYS’ program by many stakeholders
evident in other codes such as “Process” and excessive “Cost”, by entrepreneurs critical of the
excessively bureaucratic process of the application and registration process for opening
dispensaries; among physicians wary of the Program’s educational bureaucratic program of to
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become certified providers; and finally among clients, who cited difficulty in finding providers,
assembling documentation, registering on the Program website, waiting for the certification card,
arranging a pharmacist consultation at the dispensary, as well as perceived stigmas of cannabis,
and excessive cost.

Chapter 3, Aim 2
Chapter 3 of this dissertation, based upon Aim 2, was a study of the cost-effectiveness of
adding medical cannabis to opioid analgesic medication in the management of chronic pain in
patients with sickle cell disease using a decision tree model analyzed in TreeAge Pro to simulate
the cost and clinical outcomes. Probabilities, costs, and quality of life utility weights associated
with opioid use and chronic pain among patients treated with medical cannabis versus the
standard-of-care were derived from published literature. Primary outcomes included medication
costs and health-related quality of life (measured in adjusted life years, QALYs). The analysis
was carried out from a healthcare sector perspective with a time horizon of one year. Medication
costs associated with chronic pain treatment involving cannabis and opioids were expressed in
2017 US$. Incremental cost-effectiveness ratios were calculated by comparing cannabis-assisted
treatment with opioid-only standard-of-care. One-way sensitivity analyses and threshold analyses
were performed to assess parameter uncertainty. Cannabis-assisted treatment is estimated to
reduce addiction by 11.5% among SCD patients previously addicted to opioids and improve
chronic pain control from 56% to 76%. On average, cannabis-assisted treatment increased
monthly pain management medication costs by $1781.21 per person compared to opioid
analgesic treatment alone ($6037.61 vs. $4,256.40) and produced 0.06 more QALYs per person
(0.58 vs. 0.52 QALYs). The resulting incremental cost-effectiveness ratio was
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$27,219.78/QALY gained. Based on a commonly used $100,000/QALY willingness-to-pay
threshold, cannabis-assisted treatment was very cost-effective compared to the opioid-only
strategy. Sensitivity analyses suggested that these results were robust against a wide range of
parameter values. The use of medical cannabis for chronic pain management in patients with
sickle cell disease is a cost-effective intervention when compared to the current standard-of-care
of opioid analgesics alone. With the increasing availability of medical cannabis from
dispensaries to treat chronic pain, it appears advantageous to integrate medical cannabis into the
multidisciplinary management of sickle cell disease, and other chronic pain disorders.

Chapter 4, Aim 3
Chapter 4 of this dissertation, based upon Aim 3, was an analysis of the NYS Medical
Marijuana Program seen through the lived experiences of a convenience sample of 20 subjects
accessing and utilizing the medical marijuana program at a single dispensary in upstate New
York through Vireo Health. Study subjects who met study entrance criteria were all diagnosed
with cancer-related neuropathic pain and willing to undergo a qualitative in-depth, semistructured interview study of their lived experiences of a cohort of subjects with cancer-related
neuropathic management in nearly all cases with opioids based medication. The study design
was to capture personal, interpersonal relationships critical to their care, community dispensary,
and public policy concerns pertinent to the SEF of Chapter 2, and relevant to their disease and
health promotion.
The themes that emerged centered on their lived experiences of cancer and its treatment,
perceptions and experiences of pain management strategies, perceived benefits of medical
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cannabis, enablers of improved pain management, and barriers to pain management. This
population of clients presented experiences and perceptions of living with cancer, treatments of
cancer, pain management strategies, and impact on their quality of life that varied dramatically
both between and within individual experiences. Prior to adding CBMs into pain management
strategies, the majority of participants had been managing pain with opioid-based medications,
with varying levels of success. Subject’s reasons for altering their pain management strategies
included failure to achieve any pain control with prescribed opioids, inability to attain sufficient
pain and symptom control, or experiences of severe side effects. The subjects who pursued CBM
cited prior experience with opioid-based medications, which made them unacceptable or
undesirable. Perceived benefits of the incorporation of CBM into pain management strategies
noted by the subjects included the improved safety profile of CBM, the improved flexibility and
control subjects had for managing their variable pain, and the reduced dependency on opioids
and other medications.
Themes surrounding enablers and barriers for improved pain management strategies
pointed to challenges resulting from the lack of full integration of CBM into the US and NYS
health systems, resulting in inconsistent awareness and knowledge about the uses of CBM,
inconsistent access including policy and logistical barriers, and disjointed processes for obtaining
pain management medications. In light of this, enablers included exposure to and availability of
knowledge and guidance around CBM as well as moral, logistical, and financial support
structures. Major barriers of navigating the system included the heavy and often prohibitive
financial costs, issues around consistency of accessibility, and lack of guidance.
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Conclusions
There is integration of health policy In NYS in regards to the marijuana industry that is
evident in the New York State’s Medical Marijuana Program that regulates the operation and
certification and accessibility of medical cannabis in accordance with the State’s belief that the
positive effects of a regulated marijuana market outweighs the potential negative impacts to
society, communities, and individuals, or the view of the FDA that it is an illicit substance
without medical use. Rather, there are clear medical uses for cannabis as shown in vast RCTs
and in limited CEAs. Notwithstanding, there are significant barriers to dispensary entrepreneurs,
prescribing physicians and patients, even when they conform to state-mandated program
policies. This applies to dispensary ownership, provider and patient certification, and accessing
cannabis. There is also stigmatization related to the acceptability of medical cannabis for the
diseases it is approved and deemed cost-effective compared to the standards of care therapy.
Viewed through the lens of public health and a socioecological framework model, medical
cannabis policy in NYS needs to be reframed as an alternative to opioid pharmacotherapy in
serious disorders such as cancer- and sickle cell disease-related neuropathic pain, in which there
is favorable cost-effectiveness. Local communities and dispensaries can help in this process
when they express the interdependence of social, environmental and individual biological
determinants. At the societal level, there must be support for cannabis in the struggle against the
widening opioid crisis.
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Implications for Health Policy
The past several decades have witnessed a dramatic increase in societal interest in not
only preventing due to contracting chronic diseases, but in recognizing the importance of social
influences on health and disease. By targeting social and environmental factors, and
interventions directed at changing interpersonal, organizational, community, and public policy,
socio-ecological models have become pivotal in understanding the contribution of society,
community, interpersonal and intrapersonal factors in disease prevention and health promotion.
The SEF, which is in fact a victim-blameless approach to disease according to Tesh and
colleagues (2), resonates well with health policy measures associated with medical cannabis
because it sets aside stigmatization. The implementation of public policy by a system-change
approach alone, according to McLeroy and colleagues (3) is unlikely to succeed in a democratic
and pluralistic society because it relies on the consent of the governed, failing to take into
account the social causation of illness, and its departure from individuals and their choices.
Socio-ecological models have proven useful over the decades in assessing public health concerns
as diverse as child abuse (4) and adolescent sports-related concussion (5).
Both quantitative and qualitative research methods have been employed in SEF
analogous models of marijuana use to guide public health policy. Berg and colleagues (6)
studied correlates of level of marijuana use and driving among 649 subjects aged 18 to 34 years,
identified through Facebook ads targeting tobacco and marijuana users noting that more frequent
use of marijuana and greater user friends led to enhanced motives and less concerns about
driving under its influence (R-squared = 0.442). The authors concluded that interventions and
campaigns addressing social norms and risk perceptions of marijuana use would be successful.
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Qualitative research methods are employed in SEF models of marijuana use to guide
public health policy. Aukje and colleagues (7) investigated the process of new policy
implementation of medical cannabis in Massachusetts in 2012, when that state legalized medical
marijuana under Chapter 369 of the Act of the Humanitarian Use of Medical Marijuana statute.
Analyzing qualitative data generated from ethnographic field notes, media reports, public
records, and in-depth interviews with medical marijuana dispensary stakeholders, health care
professionals, and patient consumers, and triangulated with a grounded theory approach, the
investigators noted gaps in transparency, communication, and education in the transition from
illegal to legal status under the Massachusetts statute that governed the regulations for patients
and caregivers, and permitted certification of physicians and the registration of marijuana
dispensary entrepreneurs. The principles of social reconstruction theory, which proposes that
most of which passes for knowledge in society is socially constructed, particularly common
sense knowledge that constitutes the reality of everyday life for most of its ordinary citizens (8)
was used by Boeri and colleagues (9) to build acceptance of CBM, highlighting the
interdependence of social, environmental and individual biological determinants.
The situation was not so different however in New York in 2014, when the Governor of
NYS, The Honorable Andrew Cuomo, signed the Compassionate Care Act into law, establishing
New York State’s Medical Marijuana Program (“Program”). Three years later, during his
Executive budget address, Governor Cuomo directed the DOH in consultation with other NYS
agencies, to evaluate the experience, consequences and effects of legalized marijuana in
neighboring states and territories, and to review the health, criminal justice and economic
impacts of regulating recreational marijuana in New York. The DOH report (10) concluded that
the positive effects of a regulated marijuana market in NYS outweighed the potential negative
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impacts. Areas that could be causes for concern could be mitigated with regulation and proper
use of public education tailored to address key populations. Incorporating proper metrics and
indicators will ensure rigorous and ongoing evaluation. Inspired by the lack of perspectives from
entrepreneurs, health care professionals, pharmacists, educators, and medical cannabis patients,
this qualitative research study was performed to address gaps in the Program, and make further
health policy recommendations using a SEF approach.
While an increasing number of patients are using cannabis for medical reasons, how can
we know whether the health benefits gained with medicinal cannabis are worth the added cost?
Cost-effectiveness analysis, as performed in the Chapter 2 study, compares the costs and health
benefits of two or more interventions to determine their value. A treatment is considered costeffective when the ratio of incremental costs to incremental health benefits, known as the ICER
is less than a health care payer's willingness to pay for the health benefit. Quality-adjusted life
years expressed in QALYs, which incorporate both quality of life and longevity, are the
recommended measure of health benefit. Conversely, treatment is considered dominated, and
categorically not cost-effective, when it is less effective but more costly than an alternative and
extendedly dominated when less effective treatment alternative to usual care with a lower ICER
value. From a US health policy standpoint, $100,000 per QALY is a commonly accepted
willingness-to-pay threshold, but expert opinion estimates that it likely ranges from $100,000 to
$300,000 per QALY (11).
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Legalization of Medical and Recreational Marijuana
There are several compelling reasons to legalize medical marijuana. The first is to make
it widely available for its medical benefits especially its analgesic potential. The second is to
integrate it along with other CBM into the multidisciplinary approach to chronic pain perhaps not
as primary therapy but as adjunctive, second- or third-line therapy based upon its anticipated
cost-savings and improvement of patients’ health related quality of life (HRQoL). The third
reason is to reduce physician and patient’s reliance on opioid pharmacotherapy, thereby
stemming the growing opioid crisis in the treatment of chronic pain.
The broader question of legalization of marijuana for recreational use is beyond the scope
of this dissertation. Doing so would replace illicit market production and distribution with an
industry in which there could be rules and regulations in which farmers, intermediaries, and
registered dispensaries, but not criminals would conduct the bulk of the trade. There are also
means of liberalizing marijuana policy even without legalization. For example, use could be
tolerated, but the production and sale limited to small amounts and treated as a civil violation.
As far as concerns about marijuana’s potential for addiction, there is little crisis among
recreational or medical marijuana users according to Caulkins and colleges (12) citing most selfdescribed users as experimenters who generally do not meet all of the criteria of the Fifth Edition
of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders
(DSM- V) (13) for drug dependence or substance-related disorder. Moreover, regular marijuana
use does not necessarily indicate dependence. Caulkins and colleagues (12) cite self-reported
surveys of recreational marijuana users that fails to support marijuana as a gateway to harder
drugs such as cocaine and heroin.
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Putting aside the question of whether to legalize marijuana, there is generally broad
agreement on how to legalize it and what policies would guide its formulation from a public
policy standpoint. This would certainly include keeping prices close to current levels,
minimizing industry incentives to encourage heavy use, limiting marketing, and discouraging the
chemical composition of products to make it more appealing, and discouraging concomitant
consumption of alcohol and nicotine. It is uncertain whether these guidelines would be necessary
or even sufficient to prevent big increases in marijuana use or other negative outcomes.
Separating medical from recreational marijuana use is necessary in this political climate
until the latter is legalized and destigmatized. The national trend toward legalization of medical
cannabis took a turn first, during President Donald Trump’s campaign when he opined that states
should have the right to manage their own policies with regard to medical and recreational
marijuana (14), and three years later, when he voiced support for the Sates Act, a bipartisan bill
that would effectively end the federal prohibition on marijuana and leave the issue up to the
states (15).
By 2019, thirty-seven states legalized marijuana for medical use. Several of them that
legalized its recreational use, including Alaska, California, Colorado, Illinois, Maine,
Massachusetts, Nevada, Oregon, Vermont, Michigan, and Washington and the District of
Columbia, also petitioned the Federal government to enforce the 2013 Cole Memorandum (16).
The latter assured states with some form of legalized marijuana use, that United States Attorneys
would not prosecute users. This was rescinded by Attorney General Jeff Sessions in 2018 and
replaced with the Sensible Enforcement of Cannabis Act, enshrining into law the protections
offered by the memo (17).
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Further Research
As the majority of patients in placebo-controlled RCTs of medicinal cannabis are
administered cannabis in addition to an existing pain regimen, there is support for exploratory
CEA studies of medical cannabis as adjunctive therapy in the treatment of chronic neuropathic
pain with and without cancer, using computer simulation to assess the cost-effectiveness of
augmenting first-line, second-line, or third-line standard therapies for neuropathic pain in
treatment-naive patients over 1 year from a US health care sector perspective.
Pop stars hospitalized and others dying of opioid overdoses have refocused the nation on
an epidemic of wide-ranging proportion that threatens the fabric of our values, and highlighting
the disparity in the risk of recreation or medical cannabis use. Over the past two decades, opioid
analgesics have become a leading pain management strategy and dispensing has tripled (18) in
parallel, the incidence of opioid use disorder and opioid overdoses have both dramatically
increased (19). To reduce these harms, patient groups, clinicians, and policymakers have called
for new strategies to address pain management and reduce use of opioid analgesics. Bachhuber
and colleagues (20) recently reviewed the state of research in chronic pain who might benefit
from medical cannabis instead of opioids. This 2018 landmark study led to an important and
rapidly expanding strategy to substituting medical cannabis for opioid medications in an effort to
address the opioid epidemic.
Several roadblocks remain to make cannabis a realistic and medically accepted
alternative to opioids. The first is the gaps in research demonstrating unequivocal benefit in pain
management using RCTs, which continue to face numerous hurdles because of the Schedule 1
status of cannabis. Although the Drug Enforcement Administration (DEA) announced policy
changes to expand the number of cannabis manufacturers, currently only one entity is authorized
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to produce and supply cannabis to US researchers (21). The cannabis products available for
research are limited in scope and not necessarily comparable to cannabis products available in
state dispensaries. Even when products are obtained for research, they typically must be
dispensed in a directly observed setting. Only a handful of US clinical trials have administered
cannabis to examine its effect on pain, and all occurred in tightly controlled human laboratory
settings at short distances and with small sample sizes of less than 100 participants (22-26).
Notwithstanding, enrolling cannabis-naïve participants in a RCT could introduce
significant biases due to its already broad use and the likelihood of participants to be invested in
a positive outcome. Others might not be motivated to enroll in a RCT because of cannabis'
widespread availability outside of the trial. Given current limitations of interventional research,
observational studies are an appealing alternative. Longitudinal cohort studies of patient-reported
pain outcomes are feasible, and even intensive assessments of pain have not been found to affect
participants' responses (27). While longitudinal cohort studies that simply compare those who
use medical cannabis to those who do not would be inescapably confounded, more complex
designs and analyses could potentially come closer to estimating causation (28).
The management of treatment-resistant chronic pain with medical cannabis has shown
promise. Haroutounian and colleagues (29) conducted an open-label, prospective cohort of 274
participants in which the primary outcome was a change in the pain symptom score and
important secondary outcomes were pain severity, interference, social and emotional disability
scores, and change in opioid consumption. At six month follow up, there were significant
changes (p<0.001) in pain symptoms, severity and interference scores, together with social and
emotional disability scores, and opioid consumption improved by 44% without serious adverse
effects. While each of these analyses has limitations, users of medical cannabis were less likely
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to suffer than a general population of chronic pain patients and the treatment allowed a
significant proportion of patients to discontinue opioid use.
While experimental clinical trials provide the most definitive proof on any cause and
effect relation between medical cannabis and reduced opioid use, such studies are difficult
because its Schedule I substance status decrees it as having no currently accepted medical use
and a high potential for abuse. Other countries have similar restrictions that pose challenges for
researchers to legally obtain cannabis or to get approval for clinical trials. Nonetheless, such
trials are also a necessary next step because they would help determine safety. Thus, states with
legalized medical cannabis need to be guided toward a policy on the ways that cannabis can be
researched and accessed by the scientific community.
An important next step for this dissertation research is to work collaboratively with Vireo
Health to extend the findings of Chapter 4, and establish algorithms for patients seeking to wean
off opioid drugs with adjunctive CBM. The goal of initially reducing a client’s opioid dose by
20% in a controlled setting in collaboration with health providers and the dispensary pharmacist
is achievable over a 2-month period of 10% per month and poses no health risk, and as shown in
Chapter 2, is cost-effective. Using a mixed methods prospective cohort design, such a study
could be performed in collaboration with Vireo health. The study would enroll 20 subjects on a
stable dose of opioids for chronic neuropathic pain associated with cancer who agree to follow a
protocol for weaning their opioid dosage with the introduction of CBMs into their pain
management regime over a set timeframe. Lived experiences and emergent themes of the
subjects could be examined with in-depth, semi-structured phone interviews at entry and exit, in
conjunction with quantitative data collected monthly with regard to the dose of opioids and
CBM, and triangulated with PEG and VAS scoring, QoL assessment, and demographic data.
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Key Strengths and Limitations
In-depth interviewing was the primary study modality in Chapters 2 and 4. In the first
study, it offered this investigator the opportunity to triangulate subjects’ interpersonal
interactions in obtaining a referral to the dispensary after certification by NYS and obtaining
cannabis at a dispensary, with their beliefs and experiences. This is preferable in public health
policy to administering written or oral surveys where the investigator must hope to ask the right
questions of a purposive convenience sample of subjects as in the pilot study of Chapter 2, to
unveil essential information about the performance of NYS’ Program. As “qualitative research
answers questions such as “what is X, and how does X vary in different circumstances, and
why?”’ rather than “how big is X or how many X’s are there?” (30), the strength of in-depth
interviewing would lead it to outperform the deductive approach of the quantitative research
paradigm lest we test an exposure. Moreover, Chapter 2 was neither a study of a specific disorder
treated by medical cannabis such as cancer-related neuropathic pain, nor was it comparing it to
another agent, whether first- or second-line, such as opioids in Chapter 4. By its very nature of
allowing subjects to use their own voice and express their conviction (31) the results of in-depth
interviewing in the pilot study of the feasibility of treating neuropathic pain in the cannabis
dispensaries in Chapter 2 allowed this investigator to actively deduce hypotheses to study the
cost-effectiveness of cannabis compared to opioids for SCD in Chapter 3, or test its utility in a
SEF model in the management of cancer-related pain in conjunction with, or instead of opioids
in Chapter 4.
Notwithstanding, in-depth interviewing has predictable limitations in regards to design,
implementation, and analysis that have already been previously reviewed. These include
potential difficulties in design, preparing for, and conducting the interviews, the tools and
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training necessary to carry it out properly; the subjectivity of responses by interviewees that is
influenced by social norms due to perceived stigma, as well as the difficulty in replicating the
findings and extrapolating and generalizing the results to a larger population. The selection
process of subjects in our two interview studies was purposive and the study cohort in Chapter 2
and 4 were chosen by Vireo Health pharmacists both because of their willingness to share their
information and experiences. While such samples have the benefit of convenience, they do not
assure, as in random sampling, that the results will generalize to the population from which they
were drawn, in these instances, neither the entire pool of Vireo Health dispensary users, nor all
participants in New York State’s Program. Neither study cohort was chosen because of a need to
address a specific policy question avoiding intentional skewing of the sample. Both cohorts were
relatively small which could have negative impact on the significance of the data, and further
affected by dropouts but there was no attrition.
The number and location of the dispensaries of the studies in both studies imparted key
strengths and weaknesses. More than one Vireo Health downstate dispensary participated in the
study of Chapter 2, while only one upstate dispensary took part in the Chapter 4 study. The
greater geographic representation in the former study likely instilled more divergent life
experiences and opinions. This was added to the opportunity for study subjects to meet more
than one pharmacist. In that regard, the results in Chapter 2 yielded a likely more valid
assessment of the Program and less so that of the dispensary alone while limiting the latter study
to a single dispensary location and pharmacist in upstate New York would instill greater
consistency controlled for the prescribing behaviors of more than pharmacist in the choice of the
cannabis product and dose. The dispensary in Upstate New York was in a more rural, remote and
less affluent setting than the downstate New York dispensaries making them non-comparable.
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An important limitation of the study in Chapter 4 was the onset of the COVID-19
pandemic. Pursuant to the February 24, 2020 executive order of NYS Governor, Honorable
Andrew Cuomo, citizens were asked to shelter-in-place and social-distance especially for the
elderly especially those with comorbid diseases such as cancer. Most physicians were advised to
practice via Telemedicine and similarly Vireo Health conducted remote visits via the internet.
Study subjects probably experienced a greater degree of isolation and many were at risk for
being lost to follow up by their health professionals. It was at this junction that the decision was
made to terminate data collection mainly after the entry interview. This did not preclude
assessing the dispensary records of drug doses and any emerging trends in the tapering of opioid
drugs concomitant with medical cannabis. There is no means of knowing the true impact of the
pandemic on our subjects without carrying out detailed interviews on that subject. However,
given the widespread alarm of devastating morbidity and mortality, it is very likely that the
subjects, like other normal citizens, were significantly distracted and fearful of contracting
COVID-19. Given the extensive publicity, it was well known that patients with comorbid disease
were at higher risk of infection and mortality mandating stricter adherence to isolation
precautions. The poorer prognosis of patients with cancer and COVID-19 infection results from
the systemic immunosuppression of a past or present malignancy and recent anticancer treatment
(32). Cancer patients followed at home represent a particularly frail population. Although with
substantial differences, the challenges, which cancer care professionals have to face during a
pandemic, are quite similar to those posed by natural disasters. Such patients, especially those
with lung cancer, should undergo vigorous screening for COVID-19 infection and avoid
unnecessary treatments that could alter their immune competence or have their dosages
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decreased in case of COVID-19 co-infection or altered immune competence (33). Thus, there
was reason to consider halting the study based upon medical caution.
The CEA of Chapter 3 compares medical cannabis to opioid medication using SCD as a
surrogate for chronic neuropathic pain. There are utility measures of HRQoL for SCD allowing a
comparison of both positive and negative effects of an intervention expressed as QALYs gained
or lost. The latter is a surrogate for the combined effects of QoL and overall health as measured
by a uniform rating scale, standard gamble, time tradeoff, or willingness to pay. By deriving
QALYs gained or lost to the relative costs of adding medical cannabis to the standard of care for
opioids in the treatment of SCD with the goal of reducing the dose of the latter by 20%, it was
possible to calculate cost-savings for this intervention. There were several key limitations to this
model. First, the presumption that a reduction of the opioid dose of 20% is achievable is well
established but there are no anecdotal or RCT of its health outcome either in terms of later opioid
addiction or outcome of SCD, or the presumptive effect societally on the opioid epidemic,
Second, this was a theoretic experiment modeled on 2017 US$ that did not include financial
costs associated with non-chronic pain SCD-related healthcare costs, or healthcare costs of
opioid overdose and addiction treatment. Third, the analyses did not include potential societal
costs associated with opioid addiction including productivity loss and costs incurred in the
criminal justice system. The inclusion of these costs would likely have further improved the
favorable cost-effectiveness of medical cannabis treatment. As further studies are performed in
the study of chronic pain in SCD, the sensitivity analyses in this study can be used to estimate
whether medical cannabis treatment is sufficiently effective to be cost-effective. Fourth, the
present CEA model did not evaluate adverse event rates. This could be obtained for future
studies based upon published prospective studies of cannabis for chronic noncancerous and
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applied to probability inputs to compare with conventional analgesia therapies. Finally, the CEA
was not modeled to ascertain the cost-effectiveness of augmenting first-, second, or third-line
standard therapy in SCD or the ideal choice of CBM product or dose. Awaiting detailed data
from published RCTs in neuropathic pain disorders for which cannabis is accepted therapy, it
will be necessary to extrapolate from other cohort studies, including the modeling experience in
Chapter 3 of SCD, and the dispensary-based study in Chapter 4 of cancer-related neuropathic
pain.

Public Health Relevance
Political ideology, conflicting medical evidence and opinions and media attention have
all affected the formulation of public health policy of medical cannabis. Recognizing that
caregivers and patients look for treatment options for unmet medical needs, in one rare instances,
the FDA recently approved the purified cannabidiol Epidolex®, produced by GW
Pharmaceuticals for the treatment of refractory seizure disorders in children age ≥2 years due to
severe myoclonic epilepsy of infancy, and Lennox-Gastaut syndrome. There are pathways for
expanded access and compassionate use of cannabinoids in the treatment of refractory seizures
due to infantile spasms and tuberous sclerosis complex by the same pharmaceutical
manufacturer. Patients with glaucoma, neuropathic pain, cancer, MS, chemotherapy-induced
nausea, and other seizure disorders, for which clinical trials have shown efficacy of medical
cannabis, await FDA approval. However, failing to legalize medical cannabis, the US DEA,
which continues to list medical cannabis as a Schedule 1 agent, and lists marijuana as an agent
without medical use, adds to the difficulty of states’ legislators to implement regulations
governing the dispensation by credentialed health care providers to patients with certified needs
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(34, 35). The diversity in the way that states have regulated medical cannabis as regards to the
permissible amount an individual can possess, as well as differences in the pathways for
provider, dispensary and patient registration and certification to be eligible for participation, and
perceptions surrounding its legitimate use, collectively add to the complexity in forming a
unified public health policy.
While the medical community and legislators debate the merits of marijuana reform,
legalization is advancing across the United States. While still prohibited under federal law,
medical marijuana is now legal in more than one-half the states, and in 8 states, medical cannabis
can be purchased by anyone older than 21 years. Federal support of state cannabis laws is critical
for the millions of patients who require the medication. Despite the contentious divisions in
American politics, marijuana legalization has found bipartisan support. The government’s own
statistics explain the decades-long, steady shift in public opinion. Every year, the US makes
575,000 arrests for marijuana possession alone, which is greater than the number of arrests for all
violent crimes combined (36). Enforcement of marijuana laws disproportionately affects our
nation’s poor communities of color, contributing to the crisis of mass incarceration. The war on
marijuana exacerbates poverty and has the potential to reduce the access to health care. The
unjust prohibition of marijuana has done more damage to public health than has abuse of the
marijuana itself.
The case for decriminalization of marijuana and legalization of medical cannabis among
physicians, according to Nathan and colleagues (37) is unsettled. While many physicians who
oppose legalization of medical cannabis continue to support legislation to decriminalize
marijuana, there are many serious problems with that position. Decriminalization prevents the
government from regulating product labeling and purity, leaving marijuana vulnerable to
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contamination and adulteration. Without knowing its potency, consumers are unable to use it
responsibly. Decriminalization still leaves marijuana in the hands of drug dealers and not
responsible vendors, and prosecutes marijuana growers and sellers thereby constricting the
supply chain and driving up its price, sustaining it as a lucrative untaxed illegal product and
providing market incentive for more competitive and violent procurement.
Contrary to the policy of alcohol prohibition that historically was repealed after only 13
years, physicians have advocated for effective regulation. Doctors for Cannabis Regulation
(DFCR), a national organization of physicians dedicated to the legalization and regulation of the
adult use of marijuana published a declaration of principles for medical cannabis regulation (38)
citing that the vast majority of adults are unharmed by the responsible use of cannabis and the lack of
evidence that cannabis is a gateway for later use of more harmful drugs. Legalization encourages honesty
in patient-doctor communication about cannabis use. Properly structured, tax revenues from cannabis
sales can fund research, education, substance abuse treatment programs, and community reinvestment.

Legalization would reduce the disproportionate impact of the criminal justice system on lowincome and minority citizens. Regulation benefits public health by enabling government
oversight of the production, testing, labelling, distribution, and sale of cannabis. An end to
prohibition creates the legal distinction between underage and adult use, differentiating its use by
responsible adults.
Concerned physicians advocate cannabis packaging and advertising that targets adults
and prohibits underage use by minors enforced by child-resistant packaging and strong penalties
for those who enable its use in children. Informed physicians may disagree about the specifics of
good regulation, but we cannot abstain from the discussion. As cannabis growers and
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pharmaceutical experts advise lawmakers on its regulation, there is an increasing need for
physicians to do so as well.
The challenge for the emerging marijuana industry is to raise standards and promote
patient and physician satisfaction. Up until now, there has been inconsistent evidence that the
industry has made efforts to conduct quality assurance activities. Some dispensaries promise that
they measure and warrant the chemical composition of each batch of their products. A
reasonable generalization regarding the current state of affairs, however, is that the cannabis that
patients purchase at the local cooperative will likely contain uncertain concentrations of
THC/CBD and other compounds, despite what the label says. A study of 75 products randomly
purchased from internet-listed dispensaries in San Francisco, Los Angeles, and Seattle showed
accurate labeling of THC/CBD content in only 17% (39). The majority (60%) were over-labeled,
(at least 10% less cannabinoid content than claimed), while 23% were under-labeled (at least
10% more cannabinoid content than labeled). This fact raises a host of other considerations,
including basic safety (might there be the presence of adulterants, congeners, contaminants,
insecticides), dose-related concerns (little or no pharmacologic effect at one end and drug-related
toxicities at the other), and potentially differing pharmacologic effects from batch to batch, just
to name a few. It also adds an additional level of uncertainty to any efforts by the clinician to
consider/discuss/counsel patients about dose, drug–drug interactions, and other routine clinical
issues that might arise around the prescription or endorsement of a new treatment.
Increasing physician comfort in signing endorsements, attestations, or certifications of the
possible efficacy of medical marijuana for a particular problem or symptom is an important goal
for the marijuana industry. Equally vital is attracting physicians to perform case reviews and to
complete the attestation paperwork that allows patients to purchase a medical marijuana ID card,
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which will then allow their patients to gain admittance and to purchase from a certified
dispensary. By reducing the uncertainty about whether the chemical composition of what
patients believe they are, purchasing is in fact that which they are being sold will allow ordering
physicians to give standard, informed medical advice.
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Appendices
Appendix 1
Interview Instrument for Chapter 2
I am interviewing you today as part of City University’s research study of New York
State’s Medical Marijuana Program. The purpose of today’s interview is to learn about the
experiences of various stakeholders involved and impacted by the process of legalization. By
understanding the factors that may shape this process from the perspectives of various
stakeholders, this study will highlight what is being done and provide recommendations for both
policy and future research.
I want to start by asking you some questions, this interview is meant to be an informal
conversation and you are encouraged to diverge into any areas that you feel are important to the
topic. With your permission, I will be audio recording this interview. This recording will be
confidential. We will not include your name or any other identifying information on the
transcript. Rest assured, the information, data, and reports that may come from this study, and
our interview today, cannot be traced back to you. Your participation in this study is voluntary.
You may refuse to answer any question or end the interview at any time without penalty.
Therefore, if at any point you need me to turn off the recorder, please feel free to say so.
We ask people to choose a pseudonym, or a fake name, that we can use for your story.
We include this name on the tape so your real name is not attached to any of this information.
What would you like your pseudonym to be? With your permission, I will start the audio
recording now.
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INTERVIEWER: State the following information after you turn on the recorder:
1. Interviewer (your) name
2. Respondent’s pseudonym
3. Date
Ice Breaker

First, I would like you to tell me a little bit about yourself without revealing specific
information that would identify you. So, can you talk about yourself in terms of what you are
doing at this time in your life, your goals, and any major experiences that affected your life so
far? Thank you for sharing this with me. Let us start talking about the topic of this study, medical
marijuana.
Personal Views

1. Can you describe what you know about medical marijuana (MM) and medical
marijuana legalization (MML)?
2. Can you speak a little bit about your views regarding MM before the MML bill
passed? [Probe: indifference, concern, advocate, activist, experiences]
3. Can you describe any ways in which your views have changed since the bill passed?
4. Can you speak a little bit about your views regarding the recreational use of
marijuana?
5. Can you describe your views on regular use of marijuana? [Probe: for yourself, your
friends, and your family members]
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6. Can you describe your views on the concept of marijuana as a “gateway drug”?
7. Can you speak a little about your views regarding medical marijuana dispensaries
(MMD) opening in this state? [Probe: diversion, dependence issues, crime]
8. Can you speak a little about how you feel about a MMD opening near where you
live? Where do you go to school or work?
9. What does the trend toward MML mean to you? [Probe: recreational marijuana, legal
repercussions, health repercussions]
10. What does the trend toward legalizing marijuana mean to you? [Probe: other drugs,
social repercussions, health repercussions]
Community Norms and Attitudes

11. Can you describe what you know about how MMLs affected states that passed MML
bills already? [Probe: positive impact, negative impact; research; debates]
12. Can you describe what you know about the process for implementing MM here in
New York? How did you learn this? [Probe: NYSDOH regulations; registration, public
meetings]
13. Can you describe what you know about the process for opening a MMD here in New
York? [Probe: NYSDOH regulations; registration, controversies]
14. What, if anything, have you heard about in your community (friends, parents, school)
regarding a MMD opening? [Probe: In the community, nearby, bans, moratoriums,
commercial boost; crime]
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15. Can you describe for me the community where you live and the community where
you go to school or work? [Probe: social and economic environment; political
environment]
16. In your opinion, how will a MMD opening in or near where you live impact the
community? Where do you go to school or work? [Probe: no impact, negative, positive,
not sure, Why?]
17. In your opinion, how do you think the members of the community where you live
would feel about an MMD opening there? The community where you go to school or
work?
18. Can you talk about who you see as the main people who will be impacted by MM in
the community where you live? Where do you go to school or work? [Probe: students,
younger youth, drug users, homeless, criminals, commercial owners]
19. How will a MMD opening in the community where you live affect you? Where do
you go to school or work? [Probe: no impact, negative, positive, not sure, Why?]
20. Can you describe anything you have heard and your own opinions regarding dangers
associated with a MMD? Of MM? Of marijuana?
21. Can you describe any side affects you know of or have heard of with the use of MM?
Can you describe how these might be resolved?
Personal Norms and Attitudes and Behaviors

22. Can you speak a little bit about the health problems you think MM may be used to
treat and why? [Probe: personal experiences, hearsay]
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23. Can you describe what you know about the process of obtaining a medical marijuana
registration card? About where MMDs will open?
24. Can you describe anything you have heard and your own opinions on MM causing a
user to engage in more risky behaviors than typical?
25. Can you describe anything you have heard and your own opinions on recreational
marijuana use causing a user to engage in more risky behaviors than typical? [Probe:
sexual behaviors, multiple partners, drug injection behaviors]
26. Can you describe any impact you think MM will have on youth in this state? [Probe:
interest, diversion, dependence, behaviors]
27. In your opinion, is there a need in terms of prevention services for young people who
might have problems with marijuana use? If so, what is the most important need for
addressing this?
28. Can you describe any health problems that you would like to use MM to treat?
29. Can you talk about any plans you have to get a MM registration card and why?
30. Can you talk about anyone you know who will be trying to obtain a MM registration
card. If so, how do you know this person? What do you think of their reasons for needing
a MM card?
31. Can you describe a time, if any, that you have obtained marijuana from someone who
used it for medical purposes? If so, please describe how you obtained it. How did you
feel about using MM illicitly? [Probe: fearful, paranoid, indifference, content, worth-it]
32. Do you think smoking marijuana regularly can be harmful? In what ways?
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33. Can you describe how easy it would be for you to obtain marijuana right now if you
wanted it?
34. What do you think your close friends think about using medical marijuana? About
smoking marijuana for recreational purposes? About using it regularly?
35. If you plan to apply for a registration card, how do you think this will affect your life?
Your future? Your parents? What are your concerns? [Probe: legality, diversion,
dependence, cost]
Physician Specific Questions

36. Can you describe the process of prescribing MM to a patient?
37. Can you discuss how comfortable you are with prescribing MM to a patient?
38. Can you describe the process of being registered to prescribe MM?
39. How comfortable do you think most physicians you know would be with becoming
registered? In addition, with prescribing MM to a patient? Why?
Patient Specific Questions

40. Can you describe what you know about cost, insurance coverage, and financial
subsidies for MM?
41. Can you discuss how comfortable you are with talking with your physician about
MM?
Pharmacy Manager Specific Questions
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42. Can you describe the process of being able to dispense MM?
43. Can you describe what you know of the cost structure, insurance coverage, or
financial subsidies for MM?
Great! Now if we can just wrap up with a few standard demographic questions for context.
Demographics

1. What is your gender?
2. What is your age?
3. How would you describe your religion?
4. What kind of area were you raised in? Urban/rural/suburban/small town?
5. How would you describe your political orientation?
6. How would you describe your current employment status?
7. Can you estimate your household’s combined annual incomes in thousands?
8. Where do you live? (Town/neighborhood)
9. What is the highest level of school you have completed or degree you have obtained?
10. How would you describe your ethnicity?
Thank you so much for sharing your experiences and making this pilot project possible.
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Appendix 2
PEG Pain Scale

VAS Using Faces
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Appendix 3
Interview Instrument for Chapter 4
You are being asked to participate in a research study because you and your physician
have agreed to follow a protocol of using medical cannabis to manage your cancer-related pain
while weaning down on your opioid dosage.
Purpose: The purpose of today’s interview is to learn about the lived experiences of
patients in New York with cancer-related pain management strategies, specifically the
experience of using medical cannabis to manage cancer-related pain while reducing opioid
dosage. In the first interview, this study seeks to understand your experiences with an opioiddriven pain management strategy. The interview will be repeated at the end of the three months
in which you, your physician and your Vireo Pharmacist have followed a protocol of weening
your opioid dosage down by introducing medical cannabis into your pain management strategy.
Each interview will ask in-depth questions about your health, experiences of pain and side
effects, and quality of life. If any of these questions are uncomfortable or sensitive for you, you
may wish to stop and withdraw from the research study. By gaining a clearer understanding of
the contexts and lived experiences of patients managing chronic cancer-related pain with opioids
and medical cannabis, this research study will highlight what is currently being done for
improving pain management options and provide recommendations for health policy,
interventions and future research to help improve pain management options.

Key Information: Before we begin, I want to ask for your consent to participate in this
research study. I would like to reassure you that your participation in this study is voluntary and
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you may quit the protocol, refuse to answer any question or end the interview at any time, or
remove yourself from the study without penalty or any negative impact on your relationship with
Vireo Health. Before you begin and after you complete the three-month protocol for reducing
your opioid dosage with medical cannabis, we will ask you to participate in a phone interview to
document your experiences with this process. If you choose to end the protocol early, we would
still like to conduct an exit interview with you as your experiences and choice to discontinue the
opioid reduction would be important to our research and understanding. Each of the two
interviews will be conducted over the phone and last no longer than one hour. Consent will be
audio recorded prior to each interview. During the course of these interviews, we may be
touching on topics that are sensitive, including topics such as illicit drug use and experiences of
mental health issues. You do not have to answer questions that make you feel uneasy or
embarrass you, can skip any question or end the interview at any time. Your participation in this
research will add to a greater understanding of pain management options for cancer-related
chronic pain patients and contribute to recommendations for protocols for reducing opioids and
policy regarding medical cannabis for pain management.
Procedures: If you volunteer to participate in this research study, we will ask you to do
the following:

1.

Participate in two, one-hour long in-depth phone interviews covering topics related to

your quality of life, health, and opinions and experiences with medical cannabis. Topics covered
will include occupation, social life, mental health, pain management strategies, health care
utilization, and your opinions and experiences of medical cannabis.
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2.

Consent to your Vireo pharmacist sharing de-identified data on your opioid and medical

cannabis dosages as well as your pain scores over the research study period. The data on dosage
and pain scores for all participants will be shared in a batch and names and identifying
information will be removed before they are shared to ensure that data cannot be matched to
individual study participants. This data will be used to conduct a cost-effectiveness analysis of
the opioid reduction protocol.
Audio Recording: To ensure the accuracy of the findings, the in-depth phone interviews
will be audio recorded for later transcription and analysis. You may at any time request that I
turn the audio recording device off without penalty.
Time Commitment: Your participation in this research study is expected to be two hours
in duration over a total of three months.
Potential Risks of Discomforts: During the course of the in-depth interviews, you may
find some questions ask you to describe aspects of your life or experiences that you find
sensitive, stressful or embarrassing. Discussing your state of health, symptoms, pain
management strategies and the impacts of these things on your daily quality of life may because
you discomfort.

Potential Benefits: You will not directly benefit from your participation in this research
study.
Payment for Participation: You will receive a $50 amazon gift card after your
participation in each of the two in-depth interviews, totaling $100.
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New Information: You will be notified about any new information regarding this study
that may affect your willingness to participate in a timely manner.
Confidentiality: Best efforts will be made to maintain confidentiality of any information
that is collected during this research study, and that can identify you. This information will only
be disclosed with your permission or as required by law.
The audio recordings of the interviews will be listed under a pseudonym and kept on a
password-protected computer in my possession. The transcript made from this recording will be
identified by pseudonym only and any identifying content will be coded in the transcripts. I will
not include your name or any other identifying information on the transcript.
The research team, authorized CUNY staff, and government agencies that oversee this
type of research may have access to research data and records in order to monitor the research.
Research records provided to authorized, non-CUNY individuals will not contain identifiable
information about you. Publications and/or presentations that result from this study will not
identify you by name.
We might remove identifiers from the information collected from you as part of this
study and use it for future research studies or distribute it to another investigator for future
research studies without additional informed consent.
Participants’ Rights:
• Your participation in this research study is voluntary. If you decide not to participate,
there will be no penalty to you, and you will not lose any benefits to which you are otherwise
entitled.
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• You can decide to withdraw your consent and stop participating in the research at any
time, without any penalty.
Questions, Comments or Concerns: If you have any questions, comments or concerns
about the research, you can talk to one of the following researchers:
• David Younger, MD MPH MS, primary investigator on research study and doctoral
candidate at CUNY School of Public Health and Health Policy,
David.younger89@sphmail.cuny.edu
• Betsy Eastwood, PhD MSW, faculty advisor on research study and professor at CUNY
School of Public Health and Health policy, Betsy.eastwood@sph.cuny.edu
If you have questions about your rights as a research participant, or you have comments or
concerns that you would like to discuss with someone other than the researchers, please call the
CUNY Research Compliance Administrator at 646-664-8918 or email HRPP@cuny.edu.
Alternatively, you may write to:

CUNY Office of the Vice Chancellor for Research
Attn: Research Compliance Administrator
205 East 42nd Street
New York, NY 10017
Participant Oral Consent: With your consent, I will now turn on the audio recorder and
record your oral consent. After I turn on the audio recording, I will ask you if you agree to give
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consent for both audio recording of your interview and for participating in the study and record
your answers.
I also ask participants to choose a pseudonym, or a fake name, that we can use for your
story. I will include this name on the audio recording, so your real name is not attached to any of
this information. What would you like your pseudonym to be?
Pseudonym: ___________________________

Can I turn on the recording device now?
[If the participant gives consent, turn on the audio recording device]
Interviewer states the following information after turning on the recorder:
1) Interviewer name
2) Respondent’s pseudonym
3) Date
Participant Oral Consent for Audio Recording:
Do you agree to audio recording of this interview?
Participant Oral Consent for Participation:
Do you agree to participate in this research study?
A copy of this consent information will be provided to you to keep.
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Interview Guide

Before we begin, do you have any questions?
Is it okay if we get started?
Great, let us start with some questions regarding your health and healthcare. As a reminder,
you may skip any question or end the interview at any time without repercussion:
State of Health
·

Can you tell me a bit about your health history?

·

Can you tell me about your current state of health?
o What diagnoses are you currently living with?
o Can you describe your current symptoms and levels of pain?
o How do these conditions and their associated symptoms impact your daily
routines and activities? [Probe: activities may include exercise, lifting,
climbing stairs, walking, bending, bathing, dressing, driving, work-related
activities, etc.]

·

Can you describe how your symptoms and pain are now compared to three

months ago?
Pain Management
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·

Can you describe for me what your current pain management strategy includes?

[Probe: Prescribed medications, self-medication, alternative therapies, home
remedies, etc.?]
·

Can you describe any changes your pain management strategy has undergone and

what those experiences have been like for you?
o Can you tell me about any experiences of withdrawal you have had as a
result of changes in your pain management strategies?
o Can you describe why you have changed your pain management strategy?
·

Can you tell me a bit about the side affects you experience from your pain

management strategy?
o Have these side effects changed over time?
o Have these side effects changed with medication used?
·

What does it mean to you to be living with cancer-related chronic pain?
o Does it affect your life?
o Does it affect how you see yourself?
o Does it affect how others treat you?

Health Care Utilization
·

Can you tell me about how often and when you use health care services?

·

What things influence why and when you will see a doctor or seek health care?
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·

Can you describe the processes that you go through to gain access to your pain

management medications?
o Can you describe the process you went through to be prescribed opioids?
Medical cannabis?
o Can you tell me about how you fill these prescriptions and get your
medications?
·

Can you describe what you know about cost, insurance coverage, and financial

subsidies for opioids and medical marijuana?
Great, let us move on to some questions about your life, your work life and your social life:
Occupation
·

Can you tell me about you work history?

·

Can you describe for me your current work life? [Probe: full-time, part-time,

unemployed, self-employed, student? Are the hours regular, variable, flexible?]
·

Can you tell me a bit about how you feel about your work situation?
o Are you comfortable at work?
o Do you feel secure in your situation?

·

Can you describe for me any ways in which your health affects you work life?

[Probe: cut down amount of time spent at work, alterations in work activities,
difficulties performing work tasks?]
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Social Networks
·

Can you tell me about your social life? [Probe: what is your social network like?

How often do you go out?]
·

Can you tell me a bit about your feelings regarding your social life? [Probe: do

you feel you have enough of a support network? Are you happy with your level of
engagement with friends and family?]
·

Can you describe for me any ways in which your current health affects your

social life?
·

Can you tell me about any issues of depression, loneliness, anxiety, or stress you

have experienced?
o What do you think were the reasons behind these experiences?
o How did you deal with the issue?
o Did you access any health care resources when dealing with the issue? Why
or why not?
Great, now I have just a few more questions about your opinions and those of people you know
regarding marijuana.
Norms and Attitudes Regarding Medical Marijuana
·

Can you describe your views on regular use of marijuana? [Probe: for yourself,

your friends, and your family members?]
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·

Can you speak a little about your views regarding medical marijuana dispensaries

(MMDs) opening in this state? [Probe: diversion, dependence issues, crime]
·

What does the trend toward MML mean to you? [Probe: recreational marijuana,

legal repercussions, health repercussions]
·

Can you discuss how comfortable you were with talking with your physician

about medical marijuana? Did you suggest it? Did you provider suggest it?
Miscellaneous
·

What would you describe as the greatest challenge for chronic pain management

facing cancer patients?
·

Do you have any suggestions for what may be beneficial for overcoming this

challenge?
·

Are there any topics that we did not cover in this interview that you would like to

discuss?
Thank you so much for taking the time to participate in this research study.
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